Adrian V. S. Hill

Adrian V. S. Hill's AcademicInfluence.com Rankings

Adrian V. S. Hill

Biology

#2688

World Rank

#4243

Historical Rank

Genetics

#248

World Rank

#298

Historical Rank

biology Degrees

Download Badge

Biology

Why Is Adrian V. S. Hill Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Sir Adrian Vivian Sinton Hill, is an Irish vaccinologist , Director of the Jenner Institute and Lakshmi Mittal and Family Professor of Vaccinology at the University of Oxford, an honorary Consultant Physician in Infectious Diseases, and Fellow of Magdalen College, Oxford. Hill is a leader in the field of malaria vaccine development and was a co-leader of the research team which produced the Oxford–AstraZeneca COVID-19 vaccine, along with Professor Sarah Gilbert of the Jenner Institute and Professor Andrew Pollard of the Oxford Vaccine Group.

(See a Problem?)

Adrian V. S. Hill's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls (2007) (9208)
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK (2020) (3297)
Common West African HLA antigens are associated with protection from severe malaria (1991) (1577)
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial (2020) (1480)
Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants (2007) (1421)
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial (2020) (1079)
TNF concentration in fatal cerebral, non-fatal cerebral, and uncomplicated Plasmodium falciparum malaria (1990) (884)
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials (2021) (812)
Variations in the NRAMP1 gene and susceptibility to tuberculosis in West Africans. (1998) (787)
Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara (1998) (718)
Rapid Effector Function in CD8+ Memory T Cells (1997) (682)
Molecular analysis of the association of HLA-B53 and resistance to severe malaria (1992) (665)
Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans (2004) (622)
Correction: Corrigendum: The blood-stage malaria antigen PfRH5 is susceptible to vaccine-inducible cross-strain neutralizing antibody (2011) (619)
Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans (2003) (607)
Genome-wide association study of CNVs in 16,000 cases of eight common diseases and 3,000 shared controls (2010) (600)
Toll-like receptor 4 polymorphisms and atherogenesis. (2002) (586)
The immunogenetics of human infectious diseases. (1998) (584)
In vivo antigen challenge in celiac disease identifies a single transglutaminase-modified peptide as the dominant A-gliadin T-cell epitope (2000) (572)
Natural selection of hemi- and heterozygotes for G6PD deficiency in Africa by resistance to severe malaria (1995) (566)
Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial (2001) (556)
A polymorphism that affects OCT-1 binding to the TNF promoter region is associated with severe malaria (1999) (520)
A Mal functional variant is associated with protection against invasive pneumococcal disease, bacteremia, malaria and tuberculosis (2007) (494)
Rapid detection of Mycobacterium tuberculosis infection by enumeration of antigen-specific T cells. (2001) (482)
Genetics of susceptibitlity to human infectious disease (2001) (469)
Genome-wide association study of copy number variation in 16,000 cases of eight common diseases and 3,000 shared controls (2010) (465)
Tuberculosis and chronic hepatitis B virus infection in Africans and variation in the vitamin D receptor gene. (1999) (460)
Variation in the TNF-alpha promoter region associated with susceptibility to cerebral malaria. (1994) (459)
Enhanced contact tracing and spatial tracking of Mycobacterium tuberculosis infection by enumeration of antigen-specific T cells (2001) (430)
Genomic landscape of the individual host response and outcomes in sepsis: a prospective cohort study (2016) (423)
Human genetic susceptibility to infectious disease (2012) (422)
Comprehensive, Quantitative Mapping of T Cell Epitopes in Gluten in Celiac Disease (2010) (421)
Automated binning of microsatellite alleles: problems and solutions (2006) (417)
Bayesian refinement of association signals for 14 loci in 3 common diseases (2012) (416)
Novel Adenovirus-Based Vaccines Induce Broad and Sustained T Cell Responses to HCV in Man (2012) (414)
Enhanced Immunogenicity and Protective Efficacy Against Mycobacterium tuberculosis of Bacille Calmette-Guérin Vaccine Using Mucosal Administration and Boosting with a Recombinant Modified Vaccinia Virus Ankara1 (2003) (405)
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial (2021) (404)
Human cytolytic and interferon gamma-secreting CD8+ T lymphocytes specific for Mycobacterium tuberculosis. (1998) (400)
Upregulation of TGF-beta, FOXP3, and CD4+CD25+ regulatory T cells correlates with more rapid parasite growth in human malaria infection. (2005) (399)
Direct Ex Vivo Analysis of Antigen-Specific IFN-γ-Secreting CD4 T Cells in Mycobacterium tuberculosis-Infected Individuals: Associations with Clinical Disease State and Effect of Treatment1 (2001) (395)
Vaccines against intracellular infections requiring cellular immunity (2000) (387)
Potent CD8+ T-Cell Immunogenicity in Humans of a Novel Heterosubtypic Influenza A Vaccine, MVA−NP+M1 (2011) (385)
Enumeration of T cells specific for RD1-encoded antigens suggests a high prevalence of latent Mycobacterium tuberculosis infection in healthy urban Indians. (2001) (385)
T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial (2020) (367)
Identifying Recent Adaptations in Large-Scale Genomic Data (2013) (343)
Genome-wide association analyses identifies a susceptibility locus for tuberculosis on chromosome 18q11.2 (2010) (333)
High frequencies of α-thalassaemia are the result of natural selection by malaria (1986) (327)
Genetic susceptibility to tuberculosis in Africans: a genome-wide scan. (2000) (324)
Factors influencing success of clinical genome sequencing across a broad spectrum of disorders (2015) (319)
MBL genotype and risk of invasive pneumococcal disease: a case-control study (2002) (318)
Heterozygote advantage for HLA class-II type in hepatitis B virus infection (1997) (309)
A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory (2014) (301)
Multifunctional, High-Level Cytokine-Producing Th1 Cells in the Lung, but Not Spleen, Correlate with Protection against Mycobacterium tuberculosis Aerosol Challenge in Mice (2008) (301)
A Novel Chimpanzee Adenovirus Vector with Low Human Seroprevalence: Improved Systems for Vector Derivation and Comparative Immunogenicity (2012) (295)
A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA. (2015) (295)
Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation (2013) (281)
Association of malaria parasite population structure, HLA, and immunological antagonism. (1998) (281)
Aspects of genetic susceptibility to human infectious diseases. (2006) (274)
Vaccine Vectors Derived from a Large Collection of Simian Adenoviruses Induce Potent Cellular Immunity Across Multiple Species (2012) (271)
A CD4+ T-cell immune response to a conserved epitope in the circumsporozoite protein correlates with protection from natural Plasmodium falciparum infection and disease (2004) (270)
Glucose-6-phosphate dehydrogenase deficiency and malaria (1998) (266)
Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara. (2005) (262)
Severe malarial anemia and cerebral malaria are associated with different tumor necrosis factor promoter alleles. (1999) (259)
Evolutionary relationships of human populations from an analysis of nuclear DNA polymorphisms (1986) (256)
The genomics and genetics of human infectious disease susceptibility. (2001) (252)
Memory CD8 T cell responses exceeding a large but definable threshold provide long-term immunity to malaria (2008) (251)
Enhanced Immunogenicity of CD4+ T-Cell Responses and Protective Efficacy of a DNA-Modified Vaccinia Virus Ankara Prime-Boost Vaccination Regimen for Murine Tuberculosis (2001) (250)
Preliminary Assessment of the Efficacy of a T-Cell–Based Influenza Vaccine, MVA-NP+M1, in Humans (2012) (247)
Immunisation with BCG and recombinant MVA85A induces long‐lasting, polyfunctional Mycobacterium tuberculosis‐specific CD4+ memory T lymphocyte populations (2007) (246)
Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria. (1998) (244)
Viral Booster Vaccines Improve Mycobacterium bovis BCG-Induced Protection against Bovine Tuberculosis (2009) (239)
Vaccines against malaria (2011) (237)
Enhancement of MHC class I-restricted peptide-specific T cell induction by a DNA prime/MVA boost vaccination regime. (1998) (237)
Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses (2020) (228)
Polymorphisms in interferon-induced genes and the outcome of hepatitis C virus infection: roles of MxA, OAS-1 and PKR (2003) (225)
Prime-boost vectored malaria vaccines: Progress and prospects (2010) (217)
MVA.85A Boosting of BCG and an Attenuated, phoP Deficient M. tuberculosis Vaccine Both Show Protective Efficacy Against Tuberculosis in Rhesus Macaques (2009) (215)
Association of vitamin D receptor genotype with leprosy type. (1999) (215)
Malaria vaccine developments (2004) (215)
Association of genetic variants of the chemokine receptor CCR5 and its ligands, RANTES and MCP‐2, with outcome of HCV infection (2003) (212)
Clinical Assessment of a Recombinant Simian Adenovirus ChAd63: A Potent New Vaccine Vector (2012) (207)
Induction of CD8+ T cells using heterologous prime‐boost immunisation strategies (1999) (205)
Viral vectors as vaccine platforms: deployment in sight. (2011) (202)
Strong HLA class I--restricted T cell responses in dengue hemorrhagic fever: a double-edged sword? (2001) (201)
Susceptibility to dengue hemorrhagic fever in vietnam: evidence of an association with variation in the vitamin d receptor and Fc gamma receptor IIa genes. (2002) (201)
Tumor necrosis factor promoter polymorphism and susceptibility to lepromatous leprosy. (1997) (199)
ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans. (2012) (193)
Modified vaccinia Ankara‐expressing Ag85A, a novel tuberculosis vaccine, is safe in adolescents and children, and induces polyfunctional CD4+ T cells (2009) (193)
Vaccine-elicited human T cells recognizing conserved protein regions inhibit HIV-1. (2014) (193)
Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial (2016) (190)
Common variants at 11p13 are associated with susceptibility to tuberculosis (2012) (190)
Large-scale candidate gene study of tuberculosis susceptibility in the Karonga district of northern Malawi. (2004) (187)
Prime-Boost Immunization with Adenoviral and Modified Vaccinia Virus Ankara Vectors Enhances the Durability and Polyfunctionality of Protective Malaria CD8+ T-Cell Responses (2009) (187)
Enhanced CD8 T cell immunogenicity and protective efficacy in a mouse malaria model using a recombinant adenoviral vaccine in heterologous prime-boost immunisation regimes. (2002) (183)
A major susceptibility locus for leprosy in India maps to chromosome 10p13 (2001) (179)
A Randomised, Double-Blind, Controlled Vaccine Efficacy Trial of DNA/MVA ME-TRAP Against Malaria Infection in Gambian Adults (2004) (176)
Parasite virulence and disease patterns in Plasmodium falciparum malaria. (1994) (174)
Evaluation of vaccines in the EU TB Vaccine Cluster using a guinea pig aerosol infection model of tuberculosis. (2005) (173)
Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South Africa. (2008) (172)
Interleukin-10 promoter polymorphisms and the outcome of hepatitis C virus infection (2003) (171)
Effective induction of high-titer antibodies by viral vector vaccines (2008) (171)
Differential Immunogenicity of Various Heterologous Prime-Boost Vaccine Regimens Using DNA and Viral Vectors in Healthy Volunteers1 (2005) (170)
Potent induction of focused Th1-type cellular and humoral immune responses by RTS,S/SBAS2, a recombinant Plasmodium falciparum malaria vaccine. (1999) (168)
A DNA Prime-Modified Vaccinia Virus Ankara Boost Vaccine Encoding Thrombospondin-Related Adhesion Protein but Not Circumsporozoite Protein Partially Protects Healthy Malaria-Naive Adults against Plasmodium falciparum Sporozoite Challenge (2006) (168)
Clinical Assessment of a Novel Recombinant Simian Adenovirus ChAdOx1 as a Vectored Vaccine Expressing Conserved Influenza A Antigens (2013) (167)
Calculation of liver-to-blood inocula, parasite growth rates, and preerythrocytic vaccine efficacy, from serial quantitative polymerase chain reaction studies of volunteers challenged with malaria sporozoites. (2005) (164)
Association of a polymorphism in the P2X7 gene with tuberculosis in a Gambian population. (2002) (163)
A protein particle vaccine containing multiple malaria epitopes (1997) (163)
Genetic susceptibility to infectious disease. (2003) (161)
Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors. (2011) (161)
Phase Ia Clinical Evaluation of the Safety and Immunogenicity of the Plasmodium falciparum Blood-Stage Antigen AMA1 in ChAd63 and MVA Vaccine Vectors (2012) (160)
Pre-erythrocytic malaria vaccines: towards greater efficacy (2006) (159)
A Phase 2b Randomised Trial of the Candidate Malaria Vaccines FP9 ME-TRAP and MVA ME-TRAP among Children in Kenya (2006) (157)
Heterogeneity of microsatellite mutations within and between loci, and implications for human demographic histories. (1998) (156)
Independent recombination events between the duplicated human alpha globin genes; implications for their concerted evolution. (1984) (154)
Vitamin D receptor polymorphisms and susceptibility to tuberculosis in West Africa: a case-control and family study. (2004) (154)
The immunology of malaria infection. (2000) (153)
DNA multi-CTL epitope vaccines for HIV and Plasmodium falciparum: immunogenicity in mice. (1998) (152)
Mannose binding protein deficiency is not associated with malaria, hepatitis B carriage nor tuberculosis in Africans. (1998) (151)
mtDNA control-region sequence variation suggests multiple independent origins of an "Asian-specific" 9-bp deletion in sub-Saharan Africans. (1996) (151)
Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002) (2021) (150)
Assessment of the interleukin 1 gene cluster and other candidate gene polymorphisms in host susceptibility to tuberculosis. (1998) (150)
Identification of conserved antigenic components for a cytotoxic T lymphocyte-inducing vaccine against malaria (1995) (147)
Long-Term Thermostabilization of Live Poxviral and Adenoviral Vaccine Vectors at Supraphysiological Temperatures in Carbohydrate Glass (2010) (146)
Genome-wide association study of survival from sepsis due to pneumonia: an observational cohort study (2015) (146)
Update on the clinical development of candidate malaria vaccines. (2004) (145)
Protective Immunity against Mycobacterium tuberculosis Induced by Dendritic Cells Pulsed with both CD8+- and CD4+-T-Cell Epitopes from Antigen 85A (2002) (144)
HLA class I typing by PCR: HLA-B27 and an African B27 subtype (1991) (143)
Boosting BCG with MVA85A: the first candidate subunit vaccine for tuberculosis in clinical trials. (2005) (143)
Viral vectors as vaccine platforms: from immunogenicity to impact. (2016) (141)
Population genetics: Malaria susceptibility and CD36 mutation (2000) (141)
Leprosy and the Adaptation of Human Toll-Like Receptor 1 (2010) (140)
Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial (2020) (138)
Durable Human Memory T Cells Quantifiable by Cultured Enzyme-Linked Immunospot Assays Are Induced by Heterologous Prime Boost Immunization and Correlate with Protection against Malaria1 (2005) (136)
ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice (2017) (136)
Human CD8+ CTL Specific for the Mycobacterial Major Secreted Antigen 85A1 (2000) (135)
Coated microneedle arrays for transcutaneous delivery of live virus vaccines. (2012) (135)
Polymorphism within the interferon-gamma/receptor complex is associated with pulmonary tuberculosis. (2006) (135)
Molecular analysis of HLA class II associations with hepatitis B virus clearance and vaccine nonresponsiveness (2005) (135)
Evolution, revolution and heresy in the genetics of infectious disease susceptibility (2012) (132)
Genomic modulators of gene expression in human neutrophils (2015) (132)
Naturally Processed HLA Class II Peptides Reveal Highly Conserved Immunogenic Flanking Region Sequence Preferences That Reflect Antigen Processing Rather Than Peptide-MHC Interactions1 (2001) (130)
Inducible nitric oxide synthase polymorphism and fatal cerebral malaria (1998) (130)
Establishment of an Aerosol Challenge Model of Tuberculosis in Rhesus Macaques and an Evaluation of Endpoints for Vaccine Testing (2010) (129)
High frequencies of alpha-thalassaemia are the result of natural selection by malaria. (1986) (128)
Interleukin 10-mediated immunosuppression by a variant CD4 T cell epitope of Plasmodium falciparum. (1999) (126)
Genetics of infectious diseases. (2004) (126)
Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in Mycobacterium tuberculosis-infected individuals. (2009) (125)
CD8+ T Effector Memory Cells Protect against Liver-Stage Malaria (2011) (124)
A T Cell-Inducing Influenza Vaccine for the Elderly: Safety and Immunogenicity of MVA-NP+M1 in Adults Aged over 50 Years (2012) (123)
Enhancing protective immunity to malaria with a highly immunogenic virus-like particle vaccine (2017) (123)
Shared and Distinct Aspects of the Sepsis Transcriptomic Response to Fecal Peritonitis and Pneumonia (2017) (123)
CD209 Genetic Polymorphism and Tuberculosis Disease (2008) (122)
In silico identified CCR4 antagonists target regulatory T cells and exert adjuvant activity in vaccination (2008) (122)
Evaluation of the Efficacy of ChAd63-MVA Vectored Vaccines Expressing Circumsporozoite Protein and ME-TRAP Against Controlled Human Malaria Infection in Malaria-Naive Individuals (2014) (121)
Phase 1 evaluation of 3 highly immunogenic prime-boost regimens, including a 12-month reboosting vaccination, for malaria vaccination in Gambian men. (2004) (121)
High frequencies of circulating IFN‐γ‐secreting CD8 cytotoxic T cells specific for a novel MHC class I‐restricted Mycobacterium tuberculosis epitope in M. tuberculosis‐infected subjects without disease (2000) (120)
Correlation of Memory T Cell Responses against TRAP with Protection from Clinical Malaria, and CD4+ CD25high T Cells with Susceptibility in Kenyans (2008) (120)
Synergistic DNA-MVA prime-boost vaccination regimes for malaria and tuberculosis. (2006) (120)
Evidence of Blood Stage Efficacy with a Virosomal Malaria Vaccine in a Phase IIa Clinical Trial (2008) (119)
Prime-boost immunisation strategies for tuberculosis. (2005) (119)
Analysis of the human alpha-globin gene cluster reveals a highly informative genetic locus. (1986) (118)
Progression of Plasmodium berghei through Anopheles stephensi Is Density-Dependent (2007) (118)
Thick blood film examination for Plasmodium falciparum malaria has reduced sensitivity and underestimates parasite density (2006) (117)
Variants in the SP110 gene are associated with genetic susceptibility to tuberculosis in West Africa (2006) (117)
Gene gun intradermal DNA immunization followed by boosting with modified vaccinia virus Ankara: enhanced CD8+ T cell immunogenicity and protective efficacy in the influenza and malaria models. (1999) (117)
T cells in peripheral blood after gluten challenge in coeliac disease (2005) (117)
Genetics of susceptibility to leprosy (2002) (116)
Transmission of hepatitis B virus infection in Gambian families revealed by phylogenetic analysis. (2001) (115)
Cellular immune responses induced in cattle by heterologous prime–boost vaccination using recombinant viruses and bacille Calmette–Guérin (2004) (114)
Effective induction of HIV-specific CTL by multi-epitope using gene gun in a combined vaccination regime. (1999) (114)
Quantitative real-time polymerase chain reaction for malaria diagnosis and its use in malaria vaccine clinical trials. (2005) (113)
Association of Fcgamma receptor IIa (CD32) polymorphism with severe malaria in West Africa. (2003) (113)
Use of eluted peptide sequence data to identify the binding characteristics of peptides to the insulin-dependent diabetes susceptibility allele HLA-DQ8 (DQ 3.2). (1997) (113)
High frequencies in African and non-African populations of independent mutations in the mannose binding protein gene (1992) (113)
Prime-boost strategies for malaria vaccine development (2003) (112)
Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial (2021) (110)
Absence of an association between intercellular adhesion molecule 1, complement receptor 1 and interleukin 1 receptor antagonist gene polymorphisms and severe malaria in a West African population. (1998) (110)
Naturally processed peptides from two disease-resistance-associated HLA-DR13 alleles show related sequence motifs and the effects of the dimorphism at position 86 of the HLA-DR beta chain. (1995) (110)
Coadministration of seasonal influenza vaccine and MVA-NP+M1 simultaneously achieves potent humoral and cell-mediated responses. (2014) (108)
Boosting with Poxviruses Enhances Mycobacterium bovis BCG Efficacy against Tuberculosis in Guinea Pigs (2005) (108)
Safety and immunogenicity of DNA/modified vaccinia virus ankara malaria vaccination in African adults. (2003) (108)
Altered peptide ligands narrow the repertoire of cellular immune responses by interfering with T-cell priming (1999) (107)
Interferon-alpha receptor-1 (IFNAR1) variants are associated with protection against cerebral malaria in The Gambia (2003) (107)
USE OF MINISATELLITE DNA PROBES FOR DETERMINATION OF TWIN ZYGOSITY AT BIRTH (1985) (106)
Allelic association between the NRAMP1 gene and susceptibility to tuberculosis in Guinea–Conakry (2000) (106)
Enhanced CD8+ T Cell Immune Responses and Protection Elicited against Plasmodium berghei Malaria by Prime Boost Immunization Regimens Using a Novel Attenuated Fowlpox Virus1 (2004) (106)
Anti-CD25 Antibody Enhancement of Vaccine-Induced Immunogenicity: Increased Durable Cellular Immunity with Reduced Immunodominance1 (2005) (105)
Innate Immune Responses to Human Malaria: Heterogeneous Cytokine Responses to Blood-Stage Plasmodium falciparum Correlate with Parasitological and Clinical Outcomes1 (2006) (103)
Class II cytokine receptor gene cluster is a major locus for hepatitis B persistence. (2006) (103)
Evaluating controlled human malaria infection in Kenyan adults with varying degrees of prior exposure to Plasmodium falciparum using sporozoites administered by intramuscular injection (2014) (103)
Comparison of numerous delivery systems for the induction of cytotoxic T lymphocytes by immunization (1996) (103)
Viral vectors for malaria vaccine development (2006) (101)
Single‐dose immunogenicity and protective efficacy of simian adenoviral vectors against Plasmodium berghei (2008) (101)
Safety of DNA and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers. (2003) (100)
Lack of Association between Toll-Like Receptor 2 Polymorphisms and Susceptibility to Severe Disease Caused by Staphylococcus aureus (2004) (100)
Design, recruitment, and microbiological considerations in human challenge studies. (2015) (99)
Comparative Assessment of Transmission-Blocking Vaccine Candidates against Plasmodium falciparum (2015) (99)
Malaria resistance genes: a natural selection. (1992) (98)
Ratio of Monocytes to Lymphocytes in Peripheral Blood Identifies Adults at Risk of Incident Tuberculosis Among HIV-Infected Adults Initiating Antiretroviral Therapy (2013) (98)
Functional and genetic evidence that the Mal/TIRAP allele variant 180L has been selected by providing protection against septic shock (2009) (98)
Genetic susceptibility to mycobacteria and other infectious pathogens in humans. (1998) (97)
A clinical trial of prime-boost immunisation with the candidate malaria vaccines RTS,S/AS02A and MVA-CS. (2006) (95)
Optimization of a peptide-based protocol employing IL-7 for in vitro restimulation of human cytotoxic T lymphocyte precursors. (1997) (94)
Mapping of a novel susceptibility locus suggests a role for MC3R and CTSZ in human tuberculosis. (2008) (94)
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial (2021) (93)
Protection from Plasmodium berghei infection by priming and boosting T cells to a single class I‐restricted epitope with recombinant carriers suitable for human use (1998) (93)
Maintenance of MHC polymorphism (1992) (93)
The Induction and Persistence of T Cell IFN-γ Responses after Vaccination or Natural Exposure Is Suppressed by Plasmodium falciparum1 (2007) (93)
Polymorphisms in IRF-1 associated with resistance to HIV-1 infection in highly exposed uninfected Kenyan sex workers (2007) (91)
Association between a common immunoglobulin heavy chain allele and rheumatic heart disease risk in Oceania (2017) (90)
Chimpanzee Adenovirus Vaccine Provides Multispecies Protection against Rift Valley Fever (2016) (90)
Interethnic genetic differentiation in Africa: HLA class I antigens in The Gambia. (1992) (90)
Safety of recombinant fowlpox strain FP9 and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers. (2006) (90)
HLA Associations with Malaria in Africa: Some Implications for MHC Evolution (1991) (90)
Melanesians and Polynesians share a unique alpha-thalassemia mutation. (1985) (89)
Human vaccination against RH5 induces neutralizing antimalarial antibodies that inhibit RH5 invasion complex interactions. (2017) (89)
Immunogenicities of intravenous and intramuscular administrations of modified vaccinia virus Ankara-based multi-CTL epitope vaccine for human immunodeficiency virus type 1 in mice. (1998) (89)
Enhancing Blood-Stage Malaria Subunit Vaccine Immunogenicity in Rhesus Macaques by Combining Adenovirus, Poxvirus, and Protein-in-Adjuvant Vaccines (2010) (89)
Probability of Transmission of Malaria from Mosquito to Human Is Regulated by Mosquito Parasite Density in Naïve and Vaccinated Hosts (2017) (88)
Enhancing immunogenicity and transmission-blocking activity of malaria vaccines by fusing Pfs25 to IMX313 multimerization technology (2016) (86)
Entropy production as the selection rule between different growth morphologies (1990) (85)
Recombination-Mediated Genetic Engineering of a Bacterial Artificial Chromosome Clone of Modified Vaccinia virus Ankara (MVA) (2008) (85)
Impact on Malaria Parasite Multiplication Rates in Infected Volunteers of the Protein-in-Adjuvant Vaccine AMA1-C1/Alhydrogel+CPG 7909 (2011) (84)
Prevalence of serum neutralizing antibodies against chimpanzee adenovirus 63 and human adenovirus 5 in Kenyan children, in the context of vaccine vector efficacy. (2009) (84)
Host Genetic Factors and Vaccine-Induced Immunity to Hepatitis B Virus Infection (2008) (84)
A Human Challenge Model for Mycobacterium tuberculosis Using Mycobacterium bovis Bacille Calmette-Guérin (2012) (83)
Optimising Controlled Human Malaria Infection Studies Using Cryopreserved P. falciparum Parasites Administered by Needle and Syringe (2013) (83)
Population Turnover in Remote Oceania Shortly after Initial Settlement (2018) (81)
Cellular immunity induced by the recombinant Plasmodium falciparum malaria vaccine, RTS,S/AS02, in semi‐immune adults in The Gambia (2004) (81)
Safety and High Level Efficacy of the Combination Malaria Vaccine Regimen of RTS,S/AS01B With Chimpanzee Adenovirus 63 and Modified Vaccinia Ankara Vectored Vaccines Expressing ME-TRAP (2016) (81)
Safety, immunogenicity and efficacy of a pre-erythrocytic malaria candidate vaccine, ICC-1132 formulated in Seppic ISA 720. (2005) (81)
Safety and Immunogenicity of Heterologous Prime-Boost Immunisation with Plasmodium falciparum Malaria Candidate Vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in Healthy Gambian and Kenyan Adults (2013) (80)
Genetics of infectious disease resistance. (1996) (80)
Rapid Effector Function in CD 8 1 Memory T Cells (1997) (78)
Language continuity despite population replacement in Remote Oceania (2018) (78)
Dose-finding study of the novel tuberculosis vaccine, MVA85A, in healthy BCG-vaccinated infants. (2011) (78)
A prime-boost immunisation regimen using DNA followed by recombinant modified vaccinia virus Ankara induces strong cellular immune responses against the Plasmodium falciparum TRAP antigen in chimpanzees. (2001) (78)
Genetic variability and linkage disequilibrium within the HLA-DP region: analysis of 15 different populations. (2001) (77)
The association between the ratio of monocytes:lymphocytes at age 3 months and risk of tuberculosis (TB) in the first two years of life (2014) (77)
Immune responses against a liver-stage malaria antigen induced by simian adenoviral vector AdCh63 and MVA prime-boost immunisation in non-human primates. (2010) (77)
Genetic susceptibility to invasive Salmonella disease (2015) (77)
Safety and Immunogenicity of Boosting BCG Vaccinated Subjects with BCG: Comparison with Boosting with a New TB Vaccine, MVA85A (2009) (76)
Microneedle Array Design Determines the Induction of Protective Memory CD8+ T Cell Responses Induced by a Recombinant Live Malaria Vaccine in Mice (2011) (76)
Consanguinity and susceptibility to infectious diseases in humans (2009) (76)
Extended Follow-Up Following a Phase 2b Randomized Trial of the Candidate Malaria Vaccines FP9 ME-TRAP and MVA ME-TRAP among Children in Kenya (2007) (76)
Demonstration of the Blood-Stage Plasmodium falciparum Controlled Human Malaria Infection Model to Assess Efficacy of the P. falciparum Apical Membrane Antigen 1 Vaccine, FMP2.1/AS01. (2016) (76)
Association of NRAMP1 polymorphism with leprosy type but not susceptibility to leprosy per se in west Africans. (2001) (75)
Comparison of Clinical and Parasitological Data from Controlled Human Malaria Infection Trials (2012) (74)
Genetic linkage of mild malaria to the major histocompatibility complex in Gambian children: study of affected sibling pairs (1997) (74)
Safety, Immunogenicity, and Efficacy of Prime-Boost Immunization with Recombinant Poxvirus FP9 and Modified Vaccinia Virus Ankara Encoding the Full-Length Plasmodium falciparum Circumsporozoite Protein (2006) (73)
A region of chromosome 20 is linked to leprosy susceptibility in a South Indian population. (2002) (73)
Efficacy of ChAdOx1 nCoV-19 (AZD1222) Vaccine Against SARS-CoV-2 VOC 202012/01 (B.1.1.7) (2021) (72)
Partially Randomized, Non-Blinded Trial of DNA and MVA Therapeutic Vaccines Based on Hepatitis B Virus Surface Protein for Chronic HBV Infection (2011) (72)
Can growth inhibition assays (GIA) predict blood-stage malaria vaccine efficacy? (2012) (71)
IFITM3 and Susceptibility to Respiratory Viral Infections in the Community (2013) (71)
Boosting BCG with Recombinant Modified Vaccinia Ankara Expressing Antigen 85A: Different Boosting Intervals and Implications for Efficacy Trials (2007) (71)
Precursor frequency analysis of cytotoxic T lymphocytes to pre-erythrocytic antigens of Plasmodium falciparum in West Africa. (1997) (71)
Fine mapping of a putative tuberculosis-susceptibility locus on chromosome 15q11-13 in African families. (2002) (71)
Tailoring subunit vaccine immunogenicity: Maximizing antibody and T cell responses by using combinations of adenovirus, poxvirus and protein-adjuvant vaccines against Plasmodium falciparum MSP1☆ (2010) (71)
Single-Dose Protection against Plasmodium berghei by a Simian Adenovirus Vector Using a Human Cytomegalovirus Promoter Containing Intron A (2008) (71)
A Plasmodium falciparum candidate vaccine based on a six-antigen polyprotein encoded by recombinant poxviruses (2003) (71)
Cytotoxic T cells in HIV2 seropositive Gambians. Identification of a virus-specific MHC-restricted peptide epitope. (1993) (70)
A phase IIa trial of the new tuberculosis vaccine, MVA85A, in HIV- and/or Mycobacterium tuberculosis-infected adults. (2012) (70)
Genetic susceptibility to malaria and other infectious diseases: from the MHC to the whole genome (1996) (70)
Human leukocyte antigens and natural selection by malaria. (1994) (69)
Immunogenetics and genomics (2001) (69)
Dry-Coated Live Viral Vector Vaccines Delivered by Nanopatch Microprojections Retain Long-Term Thermostability and Induce Transgene-Specific T Cell Responses in Mice (2013) (69)
Host iron redistribution as a risk factor for incident tuberculosis in HIV infection: an 11-year retrospective cohort study (2013) (68)
Novel Protein and Poxvirus-Based Vaccine Combinations for Simultaneous Induction of Humoral and Cell-Mediated Immunity1 (2005) (68)
Globin genes in Micronesia: origins and affinities of Pacific Island peoples. (1990) (68)
The relationship between human effector and memory T cells measured by ex vivo and cultured ELISPOT following recent and distal priming (2009) (67)
Identification of Targets of CD8+ T Cell Responses to Malaria Liver Stages by Genome-wide Epitope Profiling (2013) (67)
Genetic analysis of host-parasite coevolution in human malaria. (1997) (67)
Rational Zika vaccine design via the modulation of antigen membrane anchors in chimpanzee adenoviral vectors (2018) (66)
CR1 Knops blood group alleles are not associated with severe malaria in the Gambia (2003) (66)
Recombinant Viral Vaccines Expressing Merozoite Surface Protein-1 Induce Antibody- and T Cell-Mediated Multistage Protection against Malaria (2011) (65)
Immunogenicity and Protective Efficacy of Prime-Boost Regimens with Recombinant ΔureC hly+Mycobacterium bovis BCG and Modified Vaccinia Virus Ankara Expressing M. tuberculosis Antigen 85A against Murine Tuberculosis (2008) (65)
Assessment of Humoral Immune Responses to Blood-Stage Malaria Antigens following ChAd63-MVA Immunization, Controlled Human Malaria Infection and Natural Exposure (2014) (64)
CISH and susceptibility to infectious diseases. (2010) (64)
Genetic Regulation of Acquired Immune Responses to Antigens ofMycobacterium tuberculosis: a Study of Twins in West Africa (2001) (64)
Large-scale candidate gene study of leprosy susceptibility in the Karonga district of northern Malawi. (2004) (64)
Interleukin-1 gene cluster polymorphisms and susceptibility to clinical malaria in a Gambian case–control study (2004) (64)
Innate Immune Responses to Human Malaria: Heterogeneous Cytokine Responses to Blood-Stage Plasmodium falciparum Correlate with Parasitological and Clinical Outcomes (2006) (64)
Unique T Cell Effector Functions Elicited by Plasmodium falciparum Epitopes in Malaria-Exposed Africans Tested by Three T Cell Assays1 (2001) (64)
The interaction of alpha thalassaemia with malaria. (1987) (63)
PTPN22 and invasive bacterial disease (2006) (63)
Early clinical trials with a new tuberculosis vaccine, MVA85A, in tuberculosis-endemic countries: issues in study design. (2006) (63)
Association of hepatitis B surface antigen carriage with severe malaria in Gambian children (1995) (61)
Polymorphism of the TRAP gene of Plasmodium falciparum (1990) (61)
Secretor polymorphism and human immunodeficiency virus infection in Senegalese women. (2000) (61)
The Ratio of Monocytes to Lymphocytes in Peripheral Blood Correlates with Increased Susceptibility to Clinical Malaria in Kenyan Children (2013) (61)
Comparative performances of machine learning methods for classifying Crohn Disease patients using genome-wide genotyping data (2019) (61)
Combining Viral Vectored and Protein-in-adjuvant Vaccines Against the Blood-stage Malaria Antigen AMA1: Report on a Phase 1a Clinical Trial (2014) (60)
Progress with new malaria vaccines. (2003) (60)
Reverse immunogenetics: from HLA-disease associations to vaccine candidates. (1996) (60)
Examination of Influenza Specific T Cell Responses after Influenza Virus Challenge in Individuals Vaccinated with MVA-NP+M1 Vaccine (2013) (60)
Human vaccination against Plasmodium vivax Duffy-binding protein induces strain-transcending antibodies (2017) (59)
Chimpanzee adenoviral vectors as vaccines for outbreak pathogens (2017) (59)
Induction of peptide‐specific primary cytotoxic T lymphocyte responses from human peripheral blood (1995) (59)
Two Human MYD88 Variants, S34Y and R98C, Interfere with MyD88-IRAK4-Myddosome Assembly (2010) (59)
Antagonists and non-toxic variants of the dominant wheat gliadin T cell epitope in coeliac disease (2005) (59)
Malaria vaccines: the stage we are at (2007) (59)
Combination of Protein and Viral Vaccines Induces Potent Cellular and Humoral Immune Responses and Enhanced Protection from Murine Malaria Challenge (2007) (57)
Transgene Optimization, Immunogenicity and In Vitro Efficacy of Viral Vectored Vaccines Expressing Two Alleles of Plasmodium falciparum AMA1 (2011) (56)
Use of complete eluted peptide sequence data from HLA-DR and -DQ molecules to predict T cell epitopes, and the influence of the nonbinding terminal regions of ligands in epitope selection. (1998) (56)
Efficacy of a Plasmodium vivax Malaria Vaccine Using ChAd63 and Modified Vaccinia Ankara Expressing Thrombospondin-Related Anonymous Protein as Assessed with Transgenic Plasmodium berghei Parasites (2013) (56)
HTLV-1, HIV-1, hepatitis B and hepatitis delta in the Pacific and South-East Asia: a serological survey (1988) (55)
Extensive genetic diversity in the HLA class II region of Africans, with a focally predominant allele, DRB1*1304. (1992) (55)
A consultation on the optimization of controlled human malaria infection by mosquito bite for evaluation of candidate malaria vaccines. (2012) (55)
A Viral Vectored Prime-Boost Immunization Regime Targeting the Malaria Pfs25 Antigen Induces Transmission-Blocking Activity (2011) (54)
Cytotoxic T lymphocytes to Plasmodium falciparum epitopes in an area of intense and perennial transmission in Tanzania (1996) (54)
New Candidate Vaccines against Blood-Stage Plasmodium falciparum Malaria: Prime-Boost Immunization Regimens Incorporating Human and Simian Adenoviral Vectors and Poxviral Vectors Expressing an Optimized Antigen Based on Merozoite Surface Protein 1 (2010) (54)
Safety and Immunogenicity of the Candidate Tuberculosis Vaccine MVA85A in West Africa (2008) (54)
Immunogenicity of the Tuberculosis Vaccine MVA85A Is Reduced by Coadministration with EPI Vaccines in a Randomized Controlled Trial in Gambian Infants (2011) (54)
A Phase Ia Study to Assess the Safety and Immunogenicity of New Malaria Vaccine Candidates ChAd63 CS Administered Alone and with MVA CS (2014) (53)
Cytotoxic T-Lymphocyte Epitopes for HLA-B53 and Other HLA Types in the Malaria Vaccine Candidate Liver-Stage Antigen 3 (2000) (53)
Immunogenicity of the candidate malaria vaccines FP9 and modified vaccinia virus Ankara encoding the pre-erythrocytic antigen ME-TRAP in 1-6 year old children in a malaria endemic area. (2006) (53)
Immune evasion in malaria: altered peptide ligands of the circumsporozoite protein (1997) (53)
CD8+ T cell‐mediated suppression of intracellular Mycobacterium tuberculosis growth in activated human macrophages (2003) (53)
Comparative assessment of vaccine vectors encoding ten malaria antigens identifies two protective liver-stage candidates (2015) (53)
The Requirement for Potent Adjuvants To Enhance the Immunogenicity and Protective Efficacy of Protein Vaccines Can Be Overcome by Prior Immunization with a Recombinant Adenovirus (2011) (53)
Direct cloning of specific genomic DNA sequences in plasmid libraries following fragment enrichment. (1985) (52)
Progress with viral vectored malaria vaccines: A multi-stage approach involving “unnatural immunity” (2015) (52)
Safety and Immunogenicity of ChAd63 and MVA ME-TRAP in West African Children and Infants (2016) (52)
Beta thalassemia in Melanesia: association with malaria and characterization of a common variant (IVS-1 nt 5 G----C). (1988) (52)
A comparison of IFNgamma detection methods used in tuberculosis vaccine trials. (2008) (51)
Association of low-density lipoprotein receptor polymorphisms and outcome of hepatitis C infection (2002) (51)
Immunogenicity and efficacy of a chimpanzee adenovirus-vectored Rift Valley Fever vaccine in mice (2013) (51)
The immunogenetics of resistance to malaria. (1999) (51)
Translating the immunogenicity of prime-boost immunization with ChAd63 and MVA ME-TRAP from malaria naive to malaria-endemic populations. (2014) (50)
Safety and Immunogenicity of a Heterologous Prime-Boost Ebola Virus Vaccine Regimen in Healthy Adults in the United Kingdom and Senegal (2018) (50)
Functional polymorphisms in the FCN2 gene are not associated with invasive pneumococcal disease. (2007) (50)
Direct processing and presentation of antigen from malaria sporozoites by professional antigen‐presenting cells in the induction of CD8+ T‐cell responses (2005) (50)
Influence of IL‐10RA and IL‐22 polymorphisms on outcome of hepatitis C virus infection (2007) (50)
Host genetic susceptibility to human tuberculosis. (1998) (50)
Six unrelated HLA-DR-matched adults recognize identical CD4+ T cell epitopes from influenza A haemagglutinin that are not simply peptides with high HLA-DR binding affinities. (1998) (50)
Prime and target immunization protects against liver-stage malaria in mice (2017) (50)
Variation in MICA and MICB genes and enhanced susceptibility to paucibacillary leprosy in South India. (2006) (49)
Investigating the Induction of Vaccine-Induced Th17 and Regulatory T Cells in Healthy, Mycobacterium bovis BCG-Immunized Adults Vaccinated with a New Tuberculosis Vaccine, MVA85A (2010) (49)
Fusion of the Mycobacterium tuberculosis Antigen 85A to an Oligomerization Domain Enhances Its Immunogenicity in Both Mice and Non-Human Primates (2012) (49)
Safety profile of the viral vectors of attenuated fowlpox strain FP9 and modified vaccinia virus Ankara recombinant for either of 2 preerythrocytic malaria antigens, ME-TRAP or the circumsporozoite protein, in children and adults in Kenya. (2006) (49)
Report of a consultation on the optimization of clinical challenge trials for evaluation of candidate blood stage malaria vaccines, 18-19 March 2009, Bethesda, MD, USA. (2009) (49)
A human Phase I/IIa malaria challenge trial of a polyprotein malaria vaccine (2011) (49)
Vaccines against Ebola virus. (2017) (48)
Broadly distributed T cell reactivity, with no immunodominant loci, to the pre‐erythrocytic antigen thrombospondin‐related adhesive protein of Plasmodium falciparum in West Africans (1999) (48)
A national DNA bank in The Gambia, West Africa, and genomic research in developing countries (2004) (48)
Blood-stage challenge for malaria vaccine efficacy trials: a pilot study with discussion of safety and potential value. (2008) (48)
Comparison of Modeling Methods to Determine Liver-to-blood Inocula and Parasite Multiplication Rates During Controlled Human Malaria Infection (2013) (48)
A bi‐allelic tetranucleotide repeat in the promoter of the human inducible nitric oxide synthase gene (1997) (47)
Genetic diversity within the HLA class II region: ten new DPB1 alleles and their population distribution. (1992) (47)
Dynamic interactions in malaria: host heterogeneity meets parasite polymorphism (1995) (47)
Molecular epidemiology of the thalassaemias (including haemoglobin E). (1992) (47)
First field efficacy trial of the ChAd63 MVA ME-TRAP vectored malaria vaccine candidate in 5-17 months old infants and children (2018) (46)
Human CD 8 1 CTL Specific for the Mycobacterial Major Secreted Antigen 85 A 1 (2000) (46)
Small Cationic DDA:TDB Liposomes as Protein Vaccine Adjuvants Obviate the Need for TLR Agonists in Inducing Cellular and Humoral Responses (2012) (45)
Helminth Infection and Eosinophilia and the Risk of Plasmodium falciparum Malaria in 1- to 6-Year-Old Children in a Malaria Endemic Area (2008) (45)
Human genetic and metabolite variation reveals that methylthioadenosine is a prognostic biomarker and an inflammatory regulator in sepsis (2017) (45)
Genetic Factors of the Disease Course after Sepsis: A Genome-Wide Study for 28 Day Mortality (2016) (45)
Towards a universal vaccine for avian influenza: Protective efficacy of modified Vaccinia virus Ankara and Adenovirus vaccines expressing conserved influenza antigens in chickens challenged with low pathogenic avian influenza virus (2013) (45)
HLA Class I Binding Motifs Derived from Random Peptide Libraries Differ at the COOH Terminus from Those of Eluted Peptides (1997) (44)
Immunogenicity and efficacy of the novel cancer vaccine based on simian adenovirus and MVA vectors alone and in combination with PD-1 mAb in a mouse model of prostate cancer (2016) (44)
Native American gene flow into Polynesia predating Easter Island settlement (2020) (44)
Chronic hepatitis C viral infection subverts vaccine‐induced T‐cell immunity in humans (2016) (44)
Microneedle-mediated immunization of an adenovirus-based malaria vaccine enhances antigen-specific antibody immunity and reduces anti-vector responses compared to the intradermal route (2014) (44)
Ex vivo interferon-gamma immune response to thrombospondin-related adhesive protein in coastal Kenyans: longevity and risk of Plasmodium falciparum infection. (2003) (43)
Safety, Immunogenicity and Efficacy of Prime-Boost Vaccination with ChAd63 and MVA Encoding ME-TRAP against Plasmodium falciparum Infection in Adults in Senegal (2016) (43)
Mortality in HIV infection is independently predicted by host iron status and SLC11A1 and HP genotypes, with new evidence of a gene-nutrient interaction. (2009) (43)
RNA and Imidazoquinolines Are Sensed by Distinct TLR7/8 Ectodomain Sites Resulting in Functionally Disparate Signaling Events (2014) (42)
Homozygosity and risk of childhood death due to invasive bacterial disease (2009) (42)
Genetics and genomics of infectious disease susceptibility. (1999) (42)
Combining Liver- and Blood-Stage Malaria Viral-Vectored Vaccines: Investigating Mechanisms of CD8+ T Cell Interference (2011) (42)
Substantially reduced pre-patent parasite multiplication rates are associated with naturally acquired immunity to Plasmodium falciparum. (2011) (41)
Polymorphism in a lincRNA Associates with a Doubled Risk of Pneumococcal Bacteremia in Kenyan Children (2016) (41)
An empirical method for the prediction of T-cell epitopes (2004) (41)
Mixed Vector Immunization With Recombinant Adenovirus and MVA Can Improve Vaccine Efficacy While Decreasing Antivector Immunity (2012) (41)
RELATIVE ROLES OF GENETIC FACTORS, DIETARY DEFICIENCY, AND INFECTION IN ANAEMIA IN VANUATU, SOUTH-WEST PACIFIC (1985) (41)
Preventing spontaneous genetic rearrangements in the transgene cassettes of adenovirus vectors (2012) (41)
Comparison of tests for association and linkage in incomplete families. (2000) (40)
Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults (2012) (40)
Polynesian origins and affinities: globin gene variants in eastern Polynesia. (1987) (40)
Host Genetic Factors and Vaccine-Induced Immunity to HBV Infection: Haplotype Analysis (2010) (40)
Searching for the human genetic factors standing in the way of universally effective vaccines (2015) (39)
Accelerating vaccine development and deployment: report of a Royal Society satellite meeting (2011) (39)
Enhanced Vaccine-Induced CD8+ T Cell Responses to Malaria Antigen ME-TRAP by Fusion to MHC Class II Invariant Chain (2014) (39)
Emergency Ebola response: a new approach to the rapid design and development of vaccines against emerging diseases. (2015) (39)
Peripheral blood monocyte-to-lymphocyte ratio at study enrollment predicts efficacy of the RTS,S malaria vaccine: analysis of pooled phase II clinical trial data (2013) (38)
Transcriptional profiling of mycobacterial antigen-induced responses in infants vaccinated with BCG at birth (2009) (38)
Heterologous Priming-Boosting Immunization of Cattle with Mycobacterium tuberculosis 85A Induces Antigen-Specific T-Cell Responses (2003) (38)
Ty Virus-Like Particles, DNA Vaccines and Modified Vaccinia Virus Ankara; Comparisons and Combinations (1999) (38)
Human microbial challenge: the ultimate animal model. (2012) (38)
HIV and HLA: Confusion or complexity? (1996) (38)
Analysis of human B-cell responses following ChAd63-MVA MSP1 and AMA1 immunization and controlled malaria infection (2014) (37)
Increased sample volume and use of quantitative reverse-transcription PCR can improve prediction of liver-to-blood inoculum size in controlled human malaria infection studies (2015) (37)
IkappaB genetic polymorphisms and invasive pneumococcal disease. (2007) (37)
Preclinical Development of an In Vivo BCG Challenge Model for Testing Candidate TB Vaccine Efficacy (2011) (37)
Safety and efficacy of novel malaria vaccine regimens of RTS,S/AS01B alone, or with concomitant ChAd63-MVA-vectored vaccines expressing ME-TRAP (2018) (37)
Th1/Th17 Cell Induction and Corresponding Reduction in ATP Consumption following Vaccination with the Novel Mycobacterium tuberculosis Vaccine MVA85A (2011) (37)
Viral Vector Malaria Vaccines Induce High-Level T Cell and Antibody Responses in West African Children and Infants (2017) (37)
Highly-Immunogenic Virally-Vectored T-cell Vaccines Cannot Overcome Subversion of the T-cell Response by HCV during Chronic Infection (2016) (36)
Sequence analysis of HLA-Bw53, a common West African allele, suggests an origin by gene conversion of HLA-B35. (1991) (36)
Induction of T Helper Type 1 and 2 Responses to 19-Kilodalton Merozoite Surface Protein 1 in Vaccinated Healthy Volunteers and Adults Naturally Exposed to Malaria (2002) (36)
TMEM203 is a binding partner and regulator of STING-mediated inflammatory signaling in macrophages (2019) (36)
The association between the ratio of monocytes: lymphocytes and risk of tuberculosis among HIV-infected postpartum women. (2014) (36)
Alpha thalassaemia in British people. (1985) (35)
Cryopreservation-related loss of antigen-specific IFNγ producing CD4+ T-cells can skew immunogenicity data in vaccine trials: Lessons from a malaria vaccine trial substudy (2017) (35)
The utility of Plasmodium berghei as a rodent model for anti-merozoite malaria vaccine assessment (2013) (35)
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil (2021) (35)
Different hematologic phenotypes are associated with the leftward (-alpha 4.2) and rightward (-alpha 3.7) alpha+-thalassemia deletions. (1987) (35)
Distinct Transcriptional and Anti-Mycobacterial Profiles of Peripheral Blood Monocytes Dependent on the Ratio of Monocytes: Lymphocytes. (2015) (35)
Genetic variants of MARCO are associated with susceptibility to pulmonary tuberculosis in a Gambian population (2013) (34)
Genome-wide association analyses identifies a susceptibility locus for tuberculosis on chromosome 18 q 11 . 2 (2019) (34)
MyD88 Adaptor-Like D96N Is a Naturally Occurring Loss-of-Function Variant of TIRAP (2010) (34)
Vaccines and global health (2011) (34)
Identification of antigens presented by MHC for vaccines against tuberculosis (2020) (34)
Estimating the burden of iron deficiency among African children (2020) (34)
An Empirical Exploration of the (Δμ)2 Genetic Distance for 213 Human Microsatellite Markers (1999) (34)
Activation-induced Markers Detect Vaccine-Specific CD4+ T Cell Responses Not Measured by Assays Conventionally Used in Clinical Trials (2018) (34)
Analysis of the human a-globin gene cluster reveals a highly informative genetic locus ( haplotype / genetic linkage / recombinatlon / polymorphism ) (34)
Early Gamma Interferon and Interleukin-2 Responses to Vaccination Predict the Late Resting Memory in Malaria-Naïve and Malaria-Exposed Individuals (2006) (33)
Association of common genetic variant with susceptibility to invasive pneumococcal disease (2002) (33)
Immunogenetics: Defence by diversity (1999) (33)
Rational development of a protective P. vivax vaccine evaluated with transgenic rodent parasite challenge models (2017) (32)
Safety and immunogenicity of the malaria candidate vaccines FP9 CS and MVA CS in adult Gambian men. (2006) (31)
Differential immunogenicity between HAdV-5 and chimpanzee adenovirus vector ChAdOx1 is independent of fiber and penton RGD loop sequences in mice (2015) (31)
Assessment of novel vaccination regimens using viral vectored liver stage malaria vaccines encoding ME-TRAP (2018) (31)
Interleukin-8 polymorphism is not associated with pulmonary tuberculosis in the gambia. (2004) (31)
Potency of a thermostabilised chimpanzee adenovirus Rift Valley Fever vaccine in cattle (2016) (31)
Controlled human malaria infection in Kenyan adults: A safe model that could accelerate assessment of novel drugs and vaccines in malaria endemic populations (2014) (31)
Positive replication and linkage disequilibrium mapping of the chromosome 21q22.1 malaria susceptibility locus (2007) (30)
A simian-adenovirus-vectored rabies vaccine suitable for thermostabilisation and clinical development for low-cost single-dose pre-exposure prophylaxis (2018) (30)
Multiple functions of human T cells generated by experimental malaria challenge (2009) (30)
'Cytotoxic T-lymphocytes against malaria and tuberculosis: from natural immunity to vaccine design' (1998) (30)
Immunopeptidomic Profiling of HLA‐A2‐Positive Triple Negative Breast Cancer Identifies Potential Immunotherapy Target Antigens (2018) (30)
An HLA-based approach to the design of a CTL-inducing vaccine against Plasmodium falciparum. (1994) (30)
(2021). Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. The Lancet, 397(10269), 99-111. (2020) (29)
Seven new DPB1 alleles and their population distribution. (1994) (29)
HIV in Africa (Communication arising): Chemokine-receptor genes and AIDS risk (2002) (29)
External Quality Assurance of Malaria Nucleic Acid Testing for Clinical Trials and Eradication Surveillance (2014) (28)
A Naturally Occurring Variant in Human TLR9, P99L, Is Associated with Loss of CpG Oligonucleotide Responsiveness (2010) (28)
Induction of CD8+ T‐lymphocyte responses to a secreted antigen of Mycobacterium tuberculosis by an attenuated vaccinia virus (2001) (28)
Low-level malaria infections detected by a sensitive polymerase chain reaction assay and use of this technique in the evaluation of malaria vaccines in an endemic area. (2007) (28)
Iron Status and Associated Malaria Risk Among African Children (2018) (28)
Alternating vector immunizations encoding pre‐erythrocytic malaria antigens enhance memory responses in a malaria endemic area (2006) (28)
Identification of frequently recognized dimorphic T-cell epitopes in plasmodium falciparum merozoite surface protein-1 in West and East Africans: lack of correlation of immune recognition and allelic prevalence. (2001) (28)
Prevalence of HBV core promoter/precore/core mutations in Gambian chronic carriers (2001) (27)
Distinct Transcriptional and Anti-Mycobacterial Profiles of Peripheral Blood Monocytes Dependent on the Ratio of Monocytes: Lymphocytes (2015) (27)
Induction of CD8(+) T cell responses and protective efficacy following microneedle-mediated delivery of a live adenovirus-vectored malaria vaccine. (2015) (27)
Boosting BCG vaccination with MVA85A down-regulates the immunoregulatory cytokine TGF-β1 (2008) (27)
Targeting Antigen to the Surface of EVs Improves the In Vivo Immunogenicity of Human and Non-human Adenoviral Vaccines in Mice (2019) (27)
An integrated expression phenotype mapping approach defines common variants in LEP, ALOX15 and CAPNS1 associated with induction of IL-6 (2009) (26)
Dimorphic Plasmodium falciparum merozoite surface protein‐1 epitopes turn off memory T cells and interfere with T cell priming (2006) (26)
Tolerability and Immunogenicity After a Late Second Dose or a Third Dose of ChAdOx1 nCoV-19 (AZD1222) (2021) (26)
Role of transfection in the priming of cytotoxic T-cells by DNA-mediated immunization. (2002) (26)
CXCR3+ T Follicular Helper Cells Induced by Co-Administration of RTS,S/AS01B and Viral-Vectored Vaccines Are Associated With Reduced Immunogenicity and Efficacy Against Malaria (2018) (26)
Response heterogeneity of human macrophages to ATP is associated with P2X7 receptor expression but not to polymorphisms in the P2RX7 promoter1 (2002) (26)
Identification of antigens presented by MHC for vaccines against tuberculosis (2020) (26)
Circulating ICAM-1 levels in falciparum malaria are high but unrelated to disease severity. (1996) (25)
A prospective study of the influence of alpha thalassaemia on morbidity from malaria and immune responses to defined Plasmodium falciparum antigens in Gambian children. (1993) (25)
Altered CD45 expression in C77G carriers influences immune function and outcome of hepatitis C infection (2006) (25)
T Cell Responses Induced by Adenoviral Vectored Vaccines Can Be Adjuvanted by Fusion of Antigen to the Oligomerization Domain of C4b-Binding Protein (2012) (25)
Splenic dendritic cell subsets prime and boost CD8 T cells and are involved in the generation of effector CD8 T cells. (2004) (25)
Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: An open-label partially-randomised ascending dose phase I trial (2022) (24)
Assessment of Immune Interference, Antagonism, and Diversion following Human Immunization with Biallelic Blood-Stage Malaria Viral-Vectored Vaccines and Controlled Malaria Infection (2013) (24)
A CD45 polymorphism associated with abnormal splicing is absent in African populations (2002) (24)
Safety and immunogenicity of heterologous prime-boost immunization with viral-vectored malaria vaccines adjuvanted with Matrix-M™. (2017) (24)
Safety and Immunogenicity of the Heterosubtypic Influenza A Vaccine MVA-NP+M1 Manufactured on the AGE1.CR.pIX Avian Cell Line (2019) (24)
Identification of Antigens Specific to Non-Tuberculous Mycobacteria: The Mce Family of Proteins as a Target of T Cell Immune Responses (2011) (24)
Transcriptional changes induced by candidate malaria vaccines and correlation with protection against malaria in a human challenge model (2015) (24)
Safety and efficacy of ChAdOx1 RVF vaccine against Rift Valley fever in pregnant sheep and goats (2019) (24)
Cellular reactivity to the p. Falciparum protein trap in adult kenyans: novel epitopes, complex cytokine patterns, and the impact of natural antigenic variation. (2006) (24)
Qualified Biolayer Interferometry Avidity Measurements Distinguish the Heterogeneity of Antibody Interactions with Plasmodium falciparum Circumsporozoite Protein Antigens (2018) (24)
Variants of the CD40 ligand gene are not associated with increased susceptibility to tuberculosis in West Africa (2003) (24)
Expression of tak1 and tram induces synergistic pro-inflammatory signalling and adjuvants DNA vaccines. (2009) (24)
Safety and Immunogenicity of Malaria Vectored Vaccines Given with Routine Expanded Program on Immunization Vaccines in Gambian Infants and Neonates: A Randomized Controlled Trial (2017) (23)
5T4 oncofoetal glycoprotein: an old target for a novel prostate cancer immunotherapy (2017) (23)
Common Genetic Variations Associated with the Persistence of Immunity following Childhood Immunization. (2019) (23)
Variants in the Mannose-binding Lectin Gene MBL2 do not Associate With Sepsis Susceptibility or Survival in a Large European Cohort (2015) (23)
Risk of nontyphoidal Salmonella bacteraemia in African children is modified by STAT4 (2018) (23)
The relative magnitude of transgene-specific adaptive immune responses induced by human and chimpanzee adenovirus vectors differs between laboratory animals and a target species (2015) (22)
Invariant Vα14 Chain NKT Cells Promote Plasmodium berghei Circumsporozoite Protein-Specific Gamma Interferon- and Tumor Necrosis Factor Alpha-Producing CD8+ T Cells in the Liver after Poxvirus Vaccination of Mice (2005) (22)
A single dose of ChAdOx1 Chik vaccine induces neutralizing antibodies against four chikungunya virus lineages in a phase 1 clinical trial (2021) (22)
Optimising Immunogenicity with Viral Vectors: Mixing MVA and HAdV-5 Expressing the Mycobacterial Antigen Ag85A in a Single Injection (2012) (22)
Tailoring a Plasmodium vivax Vaccine To Enhance Efficacy through a Combination of a CSP Virus-Like Particle and TRAP Viral Vectors (2018) (22)
T-Cell Responses in Children to Internal Influenza Antigens, 1 Year After Immunization With Pandemic H1N1 Influenza Vaccine, and Response to Revaccination With Seasonal Trivalent–inactivated Influenza Vaccine (2012) (22)
Comparing human T cell and NK cell responses in viral-based malaria vaccine trials. (2009) (21)
Association of low-density lipoprotein receptor polymorphisms and outcome of hepatitis C infection (2007) (21)
Malaria is a cause of iron deficiency in African children (2020) (21)
Changes in Serological Immunology Measures in UK and Kenyan Adults Post-controlled Human Malaria Infection (2016) (21)
Identification of host–pathogen-disease relationships using a scalable multiplex serology platform in UK Biobank (2019) (21)
Recombinant Viral-Vectored Vaccines Expressing Plasmodium chabaudi AS Apical Membrane Antigen 1: Mechanisms of Vaccine-Induced Blood-Stage Protection (2012) (21)
Recombinant Viral Vaccines Expressing Merozoite Surface Protein-1 Induce Antibody- and T Cell-Mediated Multistage Protection against Malaria (2009) (21)
Reduced Ebola vaccine responses in CMV+ young adults is associated with expansion of CD57+KLRG1+ T cells (2020) (21)
Efficacy and immunogenicity of R21/Matrix-M vaccine against clinical malaria after 2 years' follow-up in children in Burkina Faso: a phase 1/2b randomised controlled trial. (2022) (21)
Next generation vaccines: single‐dose encapsulated vaccines for improved global immunisation coverage and efficacy (2015) (20)
Safety and immunogenicity of novel 5T4 viral vectored vaccination regimens in early stage prostate cancer: a phase I clinical trial (2020) (20)
A polymorphism that reduces RANTES expression is associated with protection from death in HIV-seropositive Ugandans with advanced disease. (2006) (20)
Single Nucleotide Polymorphisms in the Toll-Like Receptor 3 and CD44 Genes Are Associated with Persistence of Vaccine-Induced Immunity to the Serogroup C Meningococcal Conjugate Vaccine (2011) (20)
Safety and Immunogenicity of a Novel Recombinant Simian Adenovirus ChAdOx2 as a Vectored Vaccine (2019) (20)
The First Norovirus Longitudinal Seroepidemiological Study From Sub-Saharan Africa Reveals High Seroprevalence of Diverse Genotypes Associated With Host Susceptibility Factors (2018) (20)
Naturally Exposed Populations Differ in Their T1 and T2 Responses to the Circumsporozoite Protein of Plasmodium falciparum (2002) (19)
Paths and timings of the peopling of Polynesia inferred from genomic networks (2021) (19)
Chromosomes with one, two, three, and four fetal globin genes: molecular and hematologic analysis. (1986) (19)
Genetic factors as determinants of infectious disease transmission in human communities. (1988) (19)
Common apolipoprotein E polymorphisms and risk of clinical malaria in the Gambia (2004) (19)
Dendritic cells infected by recombinant modified vaccinia virus Ankara retain immunogenicity in vivo despite in vitro dysfunction. (2004) (19)
Towards a multi-antigen multi-stage malaria vaccine (2014) (19)
MIG (CXCL9) is a more sensitive measure than IFN-γ of vaccine induced T-cell responses in volunteers receiving investigated malaria vaccines (2009) (19)
The ferroportin Q248H mutation protects from anemia, but not malaria or bacteremia (2019) (19)
Common NFKBIL2 polymorphisms and susceptibility to pneumococcal disease: a genetic association study (2010) (19)
Assessment of the Plasmodium falciparum Preerythrocytic Antigen UIS3 as a Potential Candidate for a Malaria Vaccine (2016) (19)
Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV (2022) (19)
HLA-DQ haplotypes in 15 different populations (2000) (18)
Safety and Immunogenicity of ChAd63/MVA Pfs25-IMX313 in a Phase I First-in-Human Trial (2021) (18)
Development of a Molecular Adjuvant to Enhance Antigen-Specific CD8+ T Cell Responses (2018) (18)
The Threshold of Protection from Liver-Stage Malaria Relies on a Fine Balance between the Number of Infected Hepatocytes and Effector CD8+ T Cells Present in the Liver (2017) (18)
A population genetic survey of the haptoglobin polymorphism in Melanesians by DNA analysis. (1986) (18)
Malaria vaccines: identifying Plasmodium falciparum liver-stage targets (2015) (18)
Antibody and T‐cell responses associated with experimental human malaria infection or vaccination show limited relationships (2015) (17)
Evolutionary relationships of human populations (1986) (17)
Immunisation against a serine protease inhibitor reduces intensity of Plasmodium berghei infection in mosquitoes. (2013) (17)
Comment on “CRTAM Confers Late-Stage Activation of CD8+ T Cells to Regulate Retention within Lymph Node” (2010) (17)
Host genetics of infectious diseases: old and new approaches converge. (1998) (17)
Validation of Multiplex Serology for human hepatitis viruses B and C, human T-lymphotropic virus 1 and Toxoplasma gondii (2019) (17)
Development of an In Vitro Assay and Demonstration of Plasmodium berghei Liver-Stage Inhibition by TRAP-Specific CD8+ T Cells (2015) (16)
Safety and immunogenicity of an FP9-vectored candidate tuberculosis vaccine (FP85A), alone and with candidate vaccine MVA85A in BCG-vaccinated healthy adults (2012) (16)
MIG and the Regulatory Cytokines IL-10 and TGF-β1 Correlate with Malaria Vaccine Immunogenicity and Efficacy (2010) (16)
What is the efficacy of the RTS,S malaria vaccine? (2011) (15)
A distinctive peptide binding motif for HLA-DRB1*0407, an HLA-DR4 subtype not associated with rheumatoid arthritis (1997) (15)
ALPHA GLOBIN GENOTYPES IN TWO NORTH EUROPEAN POPULATIONS (1986) (15)
A loss-of-function IFNAR1 allele in Polynesia underlies severe viral diseases in homozygotes (2022) (15)
Inverse Associations of Human Leukocyte Antigen and Malaria Parasite Types in Two West African Populations (2005) (15)
A Common Haplotype of the TNF Receptor 2 Gene Modulates Endotoxin Tolerance (2011) (15)
Enhancing cellular immunogenicity of MVA-vectored vaccines by utilizing the F11L endogenous promoter. (2016) (14)
Irradiated wild-type and Spa mutant Staphylococcus aureus induce anti-S. aureus immune responses in mice which do not protect against subsequent intravenous challenge. (2013) (14)
High Efficacy of a Low Dose Candidate Malaria Vaccine, R21 in 1 Adjuvant Matrix-M™, with Seasonal Administration to Children in Burkina Faso (2021) (14)
Killer-cell Immunoglobulin-like Receptor (KIR) gene profiles modify HIV disease course, not HIV acquisition in South African women (2015) (14)
Profiling the host response to malaria vaccination and malaria challenge (2015) (14)
How the current West African Ebola virus disease epidemic is altering views on the need for vaccines and is galvanizing a global effort to field-test leading candidate vaccines. (2015) (14)
Evaluation of Plasmodium vivax Cell-Traversal Protein for Ookinetes and Sporozoites as a Preerythrocytic P. vivax Vaccine (2017) (14)
CD4 Intragenic SNPs Associate With HIV-2 Plasma Viral Load and CD4 Count in a Community-Based Study From Guinea-Bissau, West Africa (2011) (14)
HLA and Infection (1992) (14)
Deletion of Fifteen Open Reading Frames from Modified Vaccinia Virus Ankara Fails to Improve Immunogenicity (2015) (13)
Mapping immune variation and var gene switching in naive hosts infected with Plasmodium falciparum (2021) (13)
Immunological considerations for SARS-CoV-2 human challenge studies (2020) (13)
CD45 variant alleles: possibly increased frequency of a novel exon 4 CD45 polymorphism in HIV seropositive Ugandans (2004) (13)
Adjuvanting a viral vectored vaccine against pre-erythrocytic malaria (2017) (13)
Alpha-thalassaemia and the malaria hypothesis. (1987) (12)
A phase IIb study to determine the safety and efficacy of candidate INfluenza Vaccine MVA-NP+M1 in combination with licensed Ina CTivated infl Uenza vaccine in adult S aged 65 years and above (INVICTUS): a study protocol (2019) (12)
Genetic variation in VAC14 is associated with bacteremia secondary to diverse pathogens in African children (2018) (12)
Adenovirus-prime and baculovirus-boost heterologous immunization achieves sterile protection against malaria sporozoite challenge in a murine model (2018) (12)
Analysis of peptide‐binding motifs for two disease associated HLA‐DR13 alleles using an M13 phage display library (1996) (12)
Analysis ofthehumana-globin genecluster reveals ahighly informative genetic locus (1986) (12)
The Population Genetics of -Thalassemia and the Malaria Hypothesis (1986) (12)
Assessment of Chimpanzee Adenovirus Serotype 63 Neutralizing Antibodies Prior to Evaluation of a Candidate Malaria Vaccine Regimen Based on Viral Vectors (2014) (12)
Recombinant vaccinia viruses for the characterization of Plasmodium falciparum-specific cytotoxic T lymphocytes: recognition of processed antigen despite limited re-stimulation efficacy. (1997) (12)
31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two (2016) (11)
Distinguishing malaria and influenza: Early clinical features in controlled human experimental infection studies☆ (2012) (11)
A P. falciparum NF54 Reporter Line Expressing mCherry-Luciferase in Gametocytes, Sporozoites, and Liver-Stages (2019) (11)
Protein particle vaccines against malaria. (1997) (11)
Phase I assessments of first-in-human administration of a novel malaria anti-sporozoite vaccine candidate, R21 in matrix-M adjuvant, in UK and Burkinabe volunteers (2019) (11)
Haptoglobin genotypes are not associated with resistance to severe malaria in The Gambia. (2002) (11)
Influence of adenovirus and MVA vaccines on the breadth and hierarchy of T cell responses (2016) (11)
Molecular markers of ethnic groups (1989) (11)
Author Correction: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses (2021) (10)
Detection of Vaccine-Induced Antibodies to Ebola Virus in Oral Fluid (2016) (10)
Quantitative PCR Evaluation of Cellular Immune Responses in Kenyan Children Vaccinated with a Candidate Malaria Vaccine (2009) (10)
A single-shot adenoviral vaccine provides hemagglutinin stalk-mediated protection against heterosubtypic influenza challenge in mice (2022) (10)
Erratum: Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans (2004) (10)
Use of gene expression studies to investigate the human immunological response to malaria infection (2019) (10)
Genome-wide association analyses identifies a susceptibility locus for tuberculosis on chromosome 18q11.2 (2011) (10)
Mixed results for a malaria vaccine (2011) (10)
Geographical distribution and disease associations of the CD45 exon 6 138G variant (2006) (10)
Identification of 34 Novel Proinflammatory Proteins in a Genome-Wide Macrophage Functional Screen (2012) (10)
Viral Booster Vaccines Improve Mycobacterium bovis BCG-Induced Protection against Bovine Tuberculosis (2011) (9)
Analysis of genetic variation in two human thyroxine‐binding plasma proteins by immunodetection after isoelectric focusing (1985) (9)
Molecular Rearrangements of the Human α‐Globin Gene Cluster (1985) (9)
Ahaptoglobinaemia in Melanesia: DNA and malarial antibody studies. (1987) (9)
Malaria vaccines. (2002) (9)
The evolution of the α- and β-globin gene clusters in human populations (1986) (9)
Interactions between Plasmodium falciparum and HLA molecules. (1994) (9)
New TB vaccine granted orphan drug status (2005) (9)
Safety and High Level Efficacy of the Combination Malaria Vaccine Regimen of RTS,S/AS01B with ChAd-MVA Vectored Vaccines Expressing ME-TRAP (2016) (9)
Immunogenicity and Protective Efficacy of Prime-Boost Regimens with Recombinant ΔureC hly + Mycobacterium bovis BCG and Modified Vaccinia Virus Ankara Expressing M. tuberculosis Antigen 85A against Murine Tuberculosis (2011) (9)
An in vitro assay to measure antibody-mediated inhibition of P. berghei sporozoite invasion against P. falciparum antigens (2017) (9)
Correction: Evidence of Blood Stage Efficacy with a Virosomal Malaria Vaccine in a Phase IIa Clinical Trial (2011) (8)
Characterization of Antigenic MHC-Class-I-Restricted T Cell Epitopes in the Glycoprotein of Ebolavirus (2018) (8)
Preclinical Development and Assessment of Viral Vectors Expressing a Fusion Antigen of Plasmodium falciparum LSA1 and LSAP2 for Efficacy against Liver-Stage Malaria (2019) (8)
Development of an in vitro Plasmodium parasite killing assay for the evaluation of cell-mediated immune responses following vaccination with pre-erythrocytic malaria vaccine candidates (2014) (8)
Immunogenicity of ChAd63 + MVA ME-TRAP in Senegalese adults (2014) (8)
HLA, malaria and dominant protective associations. (1992) (8)
Mannose-binding lectin genotypes: lack of association with susceptibility to thoracic empyema (2010) (8)
Genomewide association study of leprosy. (2010) (8)
The influence of malaria on plasma retinol (1990) (8)
Quantitative association tests of immune responses to antigens of Mycobacterium tuberculosis: a study of twins in West Africa. (2004) (8)
Evaluation of liquid culture for quantitation of Mycobacterium tuberculosis in murine models. (2007) (7)
The Ratiometric Transcript Signature MX2/GPR183 Is Consistently Associated With RTS,S-Mediated Protection Against Controlled Human Malaria Infection (2020) (7)
A VLP for validation of the Plasmodium falciparum circumsporozoite protein junctional epitope for vaccine development (2021) (7)
An empirical exploration of the (delta mu)2 genetic distance for 213 human microsatellite markers. (1999) (7)
COVID-19 vaccines: Global challenges and prospects forum recommendations (2021) (7)
Modification of Adenovirus vaccine vector-induced immune responses by expression of a signalling molecule (2020) (7)
Modeling Combinations of Pre-erythrocytic Plasmodium falciparum Malaria Vaccines (2015) (7)
PTPRC (CD45) variation and disease association studied using single nucleotide polymorphism tagging. (2008) (7)
High frequency of beta thalassaemia in a small island population in Melanesia. (1987) (6)
Human T cell responses to the antigen ESAT-6 characterize vaccine candidate and potential diagnostic test for tuberculosis (1999) (6)
Identification of Immunodominant Responses to the Plasmodium falciparum Antigens PfUIS3, PfLSA1 and PfLSAP2 in Multiple Strains of Mice (2015) (6)
A three-antigen Plasmodium falciparum DNA prime—Adenovirus boost malaria vaccine regimen is superior to a two-antigen regimen and protects against controlled human malaria infection in healthy malaria-naïve adults (2021) (6)
T-cell receptor variable alpha (TCRAV) polymorphisms in European, Chinese, South American, AfroCaribbean, and Gambian populations (1997) (6)
Genetic Polymorphisms and Invasive Pneumococcal Disease (2007) (6)
4-1BBL Enhances CD8+ T Cell Responses Induced by Vectored Vaccines in Mice but Fails to Improve Immunogenicity in Rhesus Macaques (2014) (6)
Comparison of linkage disequilibrium within and between ethnic groups (1997) (6)
Generation of Novel Plasmodium falciparum NF135 and NF54 Lines Expressing Fluorescent Reporter Proteins Under the Control of Strong and Constitutive Promoters (2020) (6)
DOPS Adjuvant Confers Enhanced Protection against Malaria for VLP-TRAP Based Vaccines (2018) (6)
Determining the validity of hospital laboratory reference intervals for healthy young adults participating in early clinical trials of candidate vaccines (2013) (6)
Clearing asymptomatic parasitaemia increases the specificity of the definition of mild febrile malaria (2007) (6)
Controlled human malaria infections using aseptic, purified cryopreserved Plasmodium falciparum sporozoites administered by needle and syringe (2014) (6)
Antibody Repertoire: Embracing Diversity (2011) (6)
Safety and Immunogenicity of ChAd 63 and MVA ME-TRAP in West African Children and Infants (6)
Prime-Boost Immunization with Adenoviral and Modified Vaccinia Virus Ankara Vectors Enhances the Durability and Polyfunctionality of Protective Malaria CD8+ T-Cell Responses (2011) (6)
Viral vectored transmission blocking vaccines against Plasmodium falciparum (2010) (6)
Genetic variants associated with non-typhoidal Salmonella bacteraemia in African children (2015) (6)
Malaria is not responsible for the selection of TCR β-subunit variable gene haplotypes in The Gambia (2002) (6)
Non-deletion haemoglobin H disease in Papua New Guinea. (1987) (6)
Booster Vaccination Against SARS-CoV-2 Induces Potent Immune Responses in People With Human Immunodeficiency Virus (2022) (5)
Elevated risk of invasive group A streptococcal disease and host genetic variation in the human leucocyte antigen locus (2019) (5)
Haemoglobinopathies and malaria: new approaches to an old hypothesis. (1987) (5)
Corrigendum to “Heterologous Two-dose Vaccination with Simian Adenovirus and Poxvirus Vectors Elicits Long-lasting Cellular Immunity to Influenza Virus A in Healthy Adults” [EBioMedicine 29 (2018) 146–154] (2018) (5)
Alpha Thalassaemia in Saudi Arabia (1983) (5)
A functional variant in TIRAP , also known as MAL , and protection against invasive pneumococcal disease , bacteraemia , malaria and tuberculosis (2009) (5)
Workshop report: Malaria vaccine development in Europe--preparing for the future. (2015) (5)
The Human Leukocyte Antigen Locus and Rheumatic Heart Disease Susceptibility in South Asians and Europeans (2020) (5)
Comparative decline in funding of European Commission malaria vaccine projects: what next for the European scientists working in this field? (2011) (5)
Heterologous prime-boost vaccination targeting MAGE-type antigens promotes tumor T-cell infiltration and improves checkpoint blockade therapy (2021) (5)
Genes and Common Diseases: Susceptibility to infectious diseases (2007) (5)
Development of an objective gene expression panel as an alternative to self-reported symptom scores in human influenza challenge trials (2017) (5)
MHC polymorphism and susceptibility to intracellular infections in humans. (1996) (4)
Identification of host–pathogen-disease relationships using a scalable multiplex serology platform in UK Biobank (2022) (4)
The Human Leukocyte Antigen Locus and Susceptibility to Rheumatic Heart Disease in South Asians and Europeans (2019) (4)
Unique TCR β-subunit variable gene haplotypes in Africans (2002) (4)
Durability of ChAdOx1 nCov-19 (AZD1222) vaccination in people living with HIV - responses to SARS-CoV-2, variants of concern and circulating coronaviruses (2021) (4)
CMV-associated T cell and NK cell terminal differentiation does not affect immunogenicity of ChAdOx1 vaccination (2022) (4)
New Candidate Vaccines against Blood-Stage Plasmodium falciparum Malaria: Prime-Boost Immunization Regimens Incorporating Human and Simian Adenoviral Vectors and Poxviral Vectors Expressing an Optimized Antigen Based on Merozoite Surface Protein 1 (2011) (4)
The evolution of the alpha- and beta-globin gene clusters in human populations. (1986) (4)
Interaction of five globin gene abnormalities in a Cambodian family (1986) (4)
Genetic susceptibility to invasive Salmonella disease (2015) (4)
The population genetics of alpha-thalassemia and the malaria hypothesis. (1986) (4)
The perpetual challenge of infectious diseases. (2012) (4)
Recombination within the human embryonic xi-globin locus: a common xi-xi chromosome produced by gene conversion of the psi xi gene. (1985) (3)
Morphologies of growth (1991) (3)
Low immunogenicity of malaria pre‐erythrocytic stages can be overcome by vaccination (2020) (3)
Human genomics of the humoral immune response against polyomaviruses (2020) (3)
Correction: Host Genetic Factors and Vaccine-Induced Immunity to Hepatitis B Virus Infection (2011) (3)
Poor CD4+ T Cell Immunogenicity Limits Humoral Immunity to P. falciparum Transmission-Blocking Candidate Pfs25 in Humans (2021) (3)
pSG.MEPfTRAP – A First Generation Malaria DNA Vaccine Vector (2007) (3)
Deep Immune Phenotyping and Single-Cell Transcriptomics Allow Identification of Circulating TRM-Like Cells Which Correlate With Liver-Stage Immunity and Vaccine-Induced Protection From Malaria (2022) (3)
Exonic single nucleotide polymorphisms within TLR3 associated with infant responses to serogroup C meningococcal conjugate vaccine. (2014) (3)
BIRC6 modifies risk of invasive bacterial infection in Kenyan children (2022) (3)
Risk of pneumococcal bacteremia in Kenyan children with glucose-6-phosphate dehydrogenase deficiency (2020) (3)
Rare Variants in MYD88, IRAK4 and IKBKG and Susceptibility to Invasive Pneumococcal Disease: A Population-Based Case-Control Study (2015) (3)
Safety and Immunogenicity of Adenovirus and Poxvirus Vectored Vaccines against a Mycobacterium Avium Complex Subspecies (2021) (3)
Corrigendum to “Heterologous Two-dose Vaccination with Simian Adenovirus and Poxvirus Vectors Elicits Long-lasting Cellular Immunity to Influenza Virus A in Healthy Adults” [EBioMedicine 29 (2018) 146–154] (S2352396418300653) (10.1016/j.ebiom.2018.02.011)) (2018) (3)
Ultra-low dose immunization and multi-component vaccination strategies enhance protection against malaria in mice (2021) (3)
Risk of pneumococcal bacteremia in Kenyan children with glucose-6-phosphate dehydrogenase deficiency (2020) (3)
Genetic susceptibility to multifactorial diseases. (1997) (2)
Author Correction: T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial (2021) (2)
A silent deletion in the beta-globin gene cluster. (1986) (2)
A novel Plasmodium vivax vaccine based on recombinant chimpanzee adenovirus ChAd63 and MVA expressing TRAP (2012) (2)
Characterisation of factors contributing to the performance of nonwoven fibrous matrices as substrates for adenovirus vectored vaccine stabilisation (2021) (2)
Imputation Performance in Latin American Populations: Improving Rare Variants Representation With the Inclusion of Native American Genomes (2022) (2)
Peripheral blood T cells induced by gluten challenge in coeliac disease target a specific molecular motif and express a gut-homing integrin (2001) (2)
Safety, immunogenicity and efficacy studies of candidate malaria vaccines FP9 and MVA encoding ME-TRAP in Kenyan children [MIM-PB-224908] (2005) (2)
DURABILITY OF IMMUNE RESPONSES INDUCED BY THREE LEADING CANDIDATE EBOLA VACCINE REGIMES; RVSV ZEBOV, CHAD3 EBO Z-MVA BN-FILO AND ADHU26. ZEBOV-MVA BN FILO (2018) (2)
Erratum: Heterozygote advantage for HLA class-II type in hepatitis B virus infection (1998) (2)
THE ROLE OF REGULATORY T CELLS IN THE CONTROL OF PARASITE GROWTH AND CLINICAL OUTCOMES FOLLOWING CONTROLLED HUMAN MALARIA INFECTION IN SEMI-IMMUNE KENYAN ADULTS (2018) (2)
HIGH LEVEL EFFICACY IN HUMANS OF A NEXT-GENERATION PLASMODIUM FALCIPARUM ANTI-SPOROZOITE VACCINE: R21 IN MATRIX-M (TM) ADJUVANT (2017) (2)
Investigating the Induction of Vaccine-Induced Th17 and Regulatory T Cells in Healthy, Mycobacterium bovis BCG Immunized Adults Vaccinated with a New Tuberculosis Vaccine, MVA85A (2011) (2)
Characterization of a novel HLA-A2 variant, A*0214, by ARMS-PCR and DNA sequencing (2004) (2)
Ancient DNA reveals five streams of migration into Micronesia and matrilocality in early Pacific seafarers (2022) (2)
682P Results from ADVANCE: A phase I/II open-label non-randomised safety and efficacy study of the viral vectored ChAdOx1-MVA 5T4 (VTP-800) vaccine in combination with PD-1 checkpoint blockade in metastatic prostate cancer (2020) (2)
Viral Vectors Expressing Group B Meningococcal Outer Membrane Proteins Induce Strong Antibody Responses but Fail to Induce Functional Bactericidal Activity in Mice. (2022) (2)
Are we all out of Africa? (reply) (1986) (2)
Incidental Diagnosis in Healthy Clinical Trial Subjects (2012) (2)
The SPf66 Malaria Vaccine: Where Do We Go From Here? (1998) (2)
Screening of viral-vectored P. falciparum pre-erythrocytic candidate vaccine antigens using chimeric rodent parasites (2021) (2)
Liposomes as vaccine adjuvants (2010) (1)
Improving delivery system for malaria vaccines (2016) (1)
Publisher Correction: Adjuvanting a viral vectored vaccine against pre-erythrocytic malaria (2019) (1)
Tackling human and animal health threats through innovative vaccinology in Africa. (2018) (1)
COVID‐19 vaccines for rapid global impact (2021) (1)
Pre-clinical development and assessment of viral vectors expressing a fusion antigen of P. falciparum LSA1 and LSAP2 for efficacy against liver-stage malaria (2019) (1)
Immunogenicity and efficacy of a chimpanzee adenovirus-vectored Rift Valley Fever vaccine in mice (2013) (1)
An in vitro assay to measure antibody-mediated inhibition of P. berghei sporozoite invasion against P. falciparum antigens (2017) (1)
Safety and exceptional immunogenicity of novel 5T4 viral vectored vaccination regimes in early stage prostate cancer: a phase I clinical trial (2020) (1)
Development of an in vitro Plasmodium parasite killing assay for the evaluation of cell-mediated immune responses following vaccination with pre-erythrocytic malaria vaccine candidates (2014) (1)
Safety and immunogenicity of a ChAdOx1 vaccine against Rift Valley fever in UK adults: an open-label, non-randomised, first-in-human phase 1 clinical trial. (2023) (1)
Corrigendum to “MIG (CXCL9) is a more sensitive measure than IFN-γ of vaccine induced T-cell responses in volunteers receiving investigated malaria vaccines” [J. Immunol. Methods 340 (2009) 33–41] (2011) (1)
HLA associated differential susceptibility to severe malaria in children from Kilifi, Kenya: A case-control study (1994) (1)
Impact of exposure to malaria and nutritional status on responses to the experimental malaria vaccine ChAd63 MVA ME-TRAP in 5-17 month-old children in Burkina Faso (2022) (1)
Identification of a gene for chronic hepatitis B virus infection by genome-wide linkage analysis family-based association studies. (2000) (1)
Heterologous Prime-Boost Schedules of Replication-Defective Adenovirus Serotype 26 and Modified Vaccinia Virus Ankara Vector Vaccines Expressing Ebola Virus Glycoprotein Are Immunogenic and Well Tolerated in Healthy Adults (2015) (1)
RTS,S/AS01 malaria vaccine in African children. (2012) (1)
Polymorphisms in the IFN-induced GNES PKR, OAS-1, MxA and the outcome of hepatitis C virus infection (2002) (1)
Corrections. Emergency Ebola response: a new approach to the rapid design and development of vaccines against emerging diseases. (2015) (1)
Celiac disease associated with HLA-DQ8 and DQ2 have different T-cell repertoires in vivo (2003) (1)
The relationship between human effector and memory T cells measured by ex vivo and cultured ELISPOT following recent and distal priming (2011) (1)
Nationwide genomic biobank in Mexico unravels demographic history and complex trait architecture from 6,057 individuals (2022) (1)
OC02_07 Genome-Wide Association Study of Susceptibility to Rheumatic Heart Disease in Oceania: Preliminary Results (2016) (1)
Dissection-independent production of Plasmodium sporozoites from whole mosquitoes (2021) (1)
PROBABILITY OF TRANSMISSION OF MALARIA FROM MOSQUITO TO HUMAN IS REGULATED BY PARASITE DENSITY IN NAIVE AND VACCINATED HOSTS (2017) (1)
Genomics and DNA Variation: Determinants of Susceptibility and Outcomes in Microbial Diseases (2011) (1)
Development of a Plasmodium vivax malaria vaccine for clinical applications using transgenic parasites, virus-like particles and recombinant viruses (2014) (1)
Bioactivity of peptides homologous to the coeliac disease-specific dominant A-gliadin T cell epitope (2001) (1)
The MHC in Host-Pathogen Evolution (1996) (1)
Evolution of allorecognition? (1996) (1)
Supplementary Information A novel susceptibility locus for tuberculosis on chromosome 11p13 downstream the WT1 gene (2016) (1)
Microbial infection & immune defence (2000) (1)
Alcock Vectors at Supraphysiological Temperatures in Carbohydrate Glass Long-Term Thermostabilization of Live Poxviral and Adenoviral Vaccine (2010) (1)
Molecular biology and human diversity: Some attempts at measuring natural selection by malaria (1996) (1)
SAFETY AND IMMUNOGENICITY OF THE NOVEL PLASMODIUM FALCIPARUM BLOOD-STAGE VACCINE CHAD63-MVA RH5 IN A PHASE IA CLINICAL TRIAL (2017) (1)
Polymorphisms in genes affecting Th1/Th2 balance influence the outcome of HBV and HCV infection. (1998) (1)
Correction: Quantitative PCR Evaluation of Cellular Immune Responses in Kenyan Children Vaccinated with a Candidate Malaria Vaccine (2011) (1)
Estimating the Hidden Burden of Iron Deficiency Among African Children (2019) (1)
A microsatellite polymorphism in the CRP gene is associated with susceptibility to invasive pneumococcal disease (2000) (0)
Leo Swadling memory vectors that primes , boosts , and sustains functional HCV-specific T cell A human vaccine strategy based on chimpanzee adenoviral and MVA (2014) (0)
NEUTRALIZING ANTIBODY TITERS TO SIMIAN ADENOVIRAL VECTORS FOLLOWING ADCH63 ME-TRAP IMMUNIZATION IN HUMANS (2009) (0)
Therapeutic vaccination against hepatitis B virus using heterologous prime boost strategy with DNA and modified vaccinia virus Ankara vectors (2003) (0)
Full title: Probability of transmission of malaria from mosquito to human is regulated by mosquito parasite density in naïve and vaccinated hosts Short title: Highly infected mosquitoes are more likely to transmit malaria (2017) (0)
Evaluation of simian adenoviral vector AdCh63 expressing MSP-1 as a candidate blood-stage malaria vaccine (2009) (0)
Humoral immunogenicity of ChAd63_MVA ME-TRAP vaccination in African infants and children (2014) (0)
New TB vaccine granted orphan drug status. Author's reply (2005) (0)
Correction: Boosting BCG with Recombinant Modified Vaccinia Ankara Expressing Antigen 85A: Different Boosting Intervals and Implications for Efficacy Trials (2011) (0)
Jenner reborn: a new vaccine institute (2009) (0)
Peripheral Blood Myeloid/Platelet:Lymphoid Ratios Predict Mortality Risk Amongst 70,917 Emergency Medical Admissions: A Cohort Study (2019) (0)
Risk of nontyphoidal Salmonella bacteraemia in African children is modified by STAT 4 Gilchrist , James J . 2018-03-09 (0)
BARCELONA VACCINE FORUM: (2011) (0)
Cytotoxic T-lymphocytes against malaria and tuberculosis: from natural immunity to vaccine design. (1998) (0)
Assessment of novel pre-erythrocytic malaria vaccines in humans (2017) (0)
SAFETY AND IMMUNOGENICITY OF A REPLICATION DEFICIENT SIMIAN ADENOVIRAL VECTORED CHIKUNGUNYA VACCINE: A PHASE I, FIRST-IN-HUMAN, DOSE ESCALATION TRIAL (2019) (0)
DNA followed by recombinant Vaccinia induces cellular and humoral immune responses against a pre-erythrocytic antigen of Plasmodium falciparum in chimpanzees (1997) (0)
Tackling human and animal health threats through innovative vaccinology in Africa (2018) (0)
DNA immunisation of mice with Plasmodium berghei antigens: Use of whole antigens or multi-epitope strings, boosting with vaccinia and protection against challenge (1997) (0)
An Ounce of HCV Prevention (2014) (0)
GRACE Network of Excellence: Genetic susceptibility to lower respiratory tract infections in Europe (2011) (0)
Comparison of the safety and immunogenicity of a candidate TB vaccine, MVA85A, given by the intramuscular or intradermal route in BCG-vaccinated adults (2011) (0)
of a Novel Heterosubtypic Influenza A Vaccine, MVA2NP1M1 (2011) (0)
Addition of immunostimulatory components to DDA-TDB adjuvant delivery system (2010) (0)
Safety and Immunogenicity of the Candidate Tuberculosis Vaccine MVA 85 A in West Africa (2017) (0)
Population Turnover in Rem ote Oceania Shortly after Initial Settlement Graphical Abstract Highlights (2018) (0)
IMMUNOGENICITY OF MALARIA-VECTORED VACCINES IS NOT AFFECTED BY CO-ADMINISTRATION WITH ROUTINE EPI VACCINES IN A RANDOMISED CONTROLLED TRIAL IN GAMBIAN INFANTS AND NEONATES (2017) (0)
Additional file 3: Figure S2. of Killer-cell Immunoglobulin-like Receptor (KIR) gene profiles modify HIV disease course, not HIV acquisition in South African women (2016) (0)
Alpha adducin 1 Gly460Trp polymorphism affects the rate of fibrosis development in chronic hepatitis C virus infection (2002) (0)
Diverse outcomes of controlled human malaria infection originate from host-intrinsic immune variation and not var gene switching (2020) (0)
in Functionally Disparate Signaling Events Distinct TLR7/8 Ectodomain Sites Resulting RNA and Imidazoquinolines Are Sensed by (2014) (0)
Risk of nontyphoidal Salmonella bacteraemia in African children is modified by STAT4 (2018) (0)
Development of novel vaccine candidates and challenge models for Plasmodium vivax (2014) (0)
Molecular epidemiology gives insight of the routes of transmission of HBV in the gambia (2000) (0)
Host genetic factors influencing the outcome of HBV infection (2002) (0)
Innate immune responses to tuberculosis vaccines (2014) (0)
Attenuated Fowlpox Virus Immunization Regimens Using a Novel Malaria by Prime Boost berghei Plasmodium and Protection Elicited against T Cell Immune Responses + Enhanced CD8 (2004) (0)
Responses to HCV in Man Novel Adenovirus-Based Vaccines Induce Broad and Sustained T Cell (2011) (0)
Overview of Heterologous Prime-Boost Immunization Strategies (2009) (0)
Fusion of the Mycobacteriumtuberculosis Antigen 85A to an Oligomerization Domain Enhances Its Immunogenicity in Both Mice and Non-Human Primates (2012) (0)
Disease State and Effect of Treatment Individuals : Associations with Clinical-Infected Mycobacterium tuberculosis-Secreting CD 4 T Cells in γ IFN-Direct Ex Vivo Analysis of Antigen-Specific (2001) (0)
Phase I/II open label nonrandomized safety and efficacy study of the viral vectored ChAdOx1-MVA 5T4 immunotherapy in combination with PD-1 checkpoint blockade in intermediate-risk localized or locally advanced prostate cancer and advanced metastatic prostate cancer. (2020) (0)
Language continuity despite population 1 replacement in Remote Oceania 2 3 (2019) (0)
One con for glob Vaccines against malaria (2011) (0)
Development and assessment of particular transmission-blocking malaria vaccines (2014) (0)
Identification of Susceptibility Genes for Tuberculosis in Southern and West Africans Using Family-Based Linkage Analysis and Linkage Disequilibrium Mapping (2003) (0)
Correction: Safety and Immunogenicity of the Candidate Tuberculosis Vaccine MVA85A in West Africa (2011) (0)
Session 7: Observing immunity: implications for rational vaccine design (2004) (0)
Immunity to mycobacterial infection (WS-061) Chairpersons: Kiyoshi Takatsu, Masaji Okada (2010) (0)
Correlate with Protection against Malaria Heterologous Prime Boost Immunization and Immunospot Assays Are Induced by Quantifiable by Cultured Enzyme-Linked Durable Human Memory T Cells (2005) (0)
Co-infection with Schistosoma haematobium modulates the gene expression profile of malaria infection in schoolchildren in Gabon (2014) (0)
525 Inducible nitric oxide (NOS2A) haplotypes and the clinical outcomes of hepatitis C virus infection (2004) (0)
Identification of conserved, CD8+ cytotoxic T cell epitopes in ESAT-6, a tuberculosis vaccine candidate (1999) (0)
Running head: IB genes and pneumococcal disease (2007) (0)
T Cell Interference + Mechanisms of CD8 Viral-Vectored Vaccines: Investigating Combining Liver- and Blood-Stage Malaria (2011) (0)
Safety and Immunogenicity of a candidate MERS-CoV Viral Vectored Vaccine: a phase I, open- labelled, first-in-human, dose-escalation trial (2020) (0)
Rapid development of a vaccine against Ebola – challenges and opportunities (2014) (0)
Using pox virus vector lacking replica to boost CD4 + T cell immune response to the antigen. (2001) (0)
Correction: Correlation of Memory T Cell Responses against TRAP with Protection from Clinical Malaria, and CD4+ CD25high T Cells with Susceptibility in Kenyans (2011) (0)
Vaccination and immunotherapy against bacteria, fungi and parasites (PP-048) (2010) (0)
Scientific Business Abstracts of the 112th Annual Meeting of the Association of Physicians of Great Britain and Ireland. (2018) (0)
Correction: MVA.85A Boosting of BCG and an Attenuated, phoP Deficient M. tuberculosis Vaccine Both Show Protective Efficacy Against Tuberculosis in Rhesus Macaques (2011) (0)
Malaria is causally associated with iron deficiency in African children (2019) (0)
ASSOCIATION OF Fc (cid:1) RECEPTOR IIa (CD32) POLYMORPHISM WITH SEVERE MALARIA IN WEST AFRICA (2003) (0)
Infection 3 Protozoal and helminth infection (SY1-5) Chairpersons: Kenji Nakanishi, Maria Yazdanbakhsh (2010) (0)
CRYOPRESERVATION RELATED LOSS OF ANTIGEN SPECIFIC IFN gamma PRODUCING CD4+T-CELLS: LESSONS FROM A MALARIA VACCINE TRIAL SUBSTUDY (2017) (0)
Single nucleotide polymorphisms in trap associate with severe malarial disease: A novel parasite virulence gene (2006) (0)
Back Cover: Immunopeptidomic Profiling of HLA-A2-Positive Triple Negative Breast Cancer Identifies Potential Immunotherapy Target Antigens (2018) (0)
Shared immunogenetic associations across common pathogens discovered through Multiplex Serology screening in UK Biobank (2019) (0)
Correlate with Parasitological and Clinical Plasmodium falciparum to Blood-Stage Malaria : Heterogeneous Cytokine Responses Innate Immune Responses to Human Sinden (2006) (0)
SAFETY, IMMUNOGENICITY AND DURABILITY OF A NOVEL MALARIA VACCINE CANDIDATE, R21 ADJUVANTED WITH AS01(B) (2017) (0)
Abstract IA11: Viral vectored vaccines for prostate cancer (2021) (0)
Immunity to mycobacterial infection (PP-061) (2010) (0)
REGULATORY T CELL-MEDIATED SUPPRESSION OF HUMAN IMMUNE RESPONSES TO INVESTIGATIONAL MALARIA VACCINES (2017) (0)
Publisher Correction: Characterisation of factors contributing to the performance of nonwoven fibrous matrices as substrates for adenovirus vectored vaccine stabilisation (2020) (0)
Clinical Evaluation of New Immunisation Strategies for Enhancing T Cell Responses against M. Tuberculosis (2003) (0)
West African twins demonstrate evidence for genetic regulation of cellular responses to secreted M. tuberculosis antigens (2000) (0)
Population Turnover in RemoteOceania Shortly after Initial Settlement Graphical Abstract Highlights (2018) (0)
Humoral and Cell-Mediated Immunity Combinations for Simultaneous Induction of Novel Protein and Poxvirus-Based Vaccine (2005) (0)
Recombinant Modified Vaccinia Virus Ankara Administration and Boosting with a Bacille Calmette-Guérin Vaccine Using Mucosal of Mycobacterium tuberculosis Efficacy Against Enhanced Immunogenicity and Protective (2003) (0)
Retention within Lymph Node'' T Cells to Regulate + Activation of CD8 Comment on ''CRTAM Confers Late-Stage (2013) (0)
Genome-wide association study of survival from sepsis due to pneumonia (2014) (0)
IDENTIFICATION OF HUMAN T CELL EPITOPES IN THE EBOLAVIRUS GLYCOPROTEIN FOLLOWING VACCINATION WITH CHAD3 EBO Z GP AND MVA BN (2017) (0)
Transcutaneous delivery of T Cell-inducing viral vector Malaria vaccines by microneedle patches (2011) (0)
Additional file 6: Figure S4. of Killer-cell Immunoglobulin-like Receptor (KIR) gene profiles modify HIV disease course, not HIV acquisition in South African women (2016) (0)
Scientific Business Abstracts of the 112th Annual Meeting of the Association of Physicians of Great Britain and Ireland. (2018) (0)
against Liver-Stage Malaria T Effector Memory Cells Protect + CD8 (0)
Polymorphisms in the IL-10 ligand and the IL-10 receptor β chain influence susceptibility to persistent HBV infection (2001) (0)
DNA- and MVA-based multi-CTL epitope vaccines for HIV and Plasmodium falciparum: Immunogenicity in mice and macaques (1997) (0)
Correction: Safety and Immunogenicity of Boosting BCG Vaccinated Subjects with BCG: Comparison with Boosting with a New TB Vaccine, MVA85A (2011) (0)
Vaccination of Mice T Cells in the Liver after Poxvirus + CD 8 Tumor Necrosis Factor Alpha-Producing Protein-Specific Gamma Interferon-and Circumsporozoite Plasmodium berghei 14 Chain NKT Cells Promote α Invariant V (2005) (0)
Dissection-independent production of a protective whole-sporozoite malaria vaccine (2020) (0)
Poxvirus, and Protein-in-Adjuvant Vaccines Macaques by Combining Adenovirus, Vaccine Immunogenicity in Rhesus Enhancing Blood-Stage Malaria Subunit (2010) (0)
Safety and immunogenicity of the heterologous prime-boost ebolavirus vaccine regimen CHAD3-EBO Z and MVA-BN (R) FILO in healthy UK adults (2015) (0)
Quantitative Association Tests of Immune Responses to Antigens of Mycobacterium Tuberculosis: A Study of Twins in West Africa (2004) (0)
COMPARATIVE ASSESSMENT OF VIRAL VECTORED AND PROTEIN-IN-ADJUVANT PLATFORMS FOR DELIVERY OF TRANSMISSION-BLOCKING VACCINE CANDIDATES AGAINST PLASMODIUM FALCIPARUM (2015) (0)
Occurring Loss-of-Function Variant of MyD 88 Adaptor-Like D 96 N Is a Naturally (2010) (0)
Developing a deployable vaccine for Africa [MIM-TL-0] (2005) (0)
Characterisation of factors contributing to the performance (2019) (0)
Correction for Nébié et al., Assessment of Chimpanzee Adenovirus Serotype 63 Neutralizing Antibodies Prior to Evaluation of a Candidate Malaria Vaccine Regimen Based on Viral Vectors (2014) (0)
The viral vectored vaccine targeting Thymosin β10 controls tumour growth in a murine model of prostate cancer (2021) (0)
New Malaria Vaccines: The DNA‐MVA Prime‐Boost Strategy (2000) (0)
within Lymph Node'' T Cells to Regulate Retention + Activation of CD8 Comment on ''CRTAM Confers Late-Stage (2011) (0)
614 Association of genetic variants of the interferon alpha receptor-2 gene with outcome of treatment of persistant HCV infection (2003) (0)
Use of gene expression studies to investigate the human immunological response to malaria infection (2019) (0)
Genomics of microbial pathogens and host–pathogen interactions (2009) (0)
Additional file 4: Figure S3. of Killer-cell Immunoglobulin-like Receptor (KIR) gene profiles modify HIV disease course, not HIV acquisition in South African women (2016) (0)
This information is current as Vaccine-Induced Blood-Stage Protection Membrane Antigen 1 : Mechanisms of AS Apical Plasmodium chabaudi Expressing Recombinant Viral-Vectored Vaccines (2012) (0)
Polymorphism in the circumsporozoite protein of Plasmodium falciparum: A novel immune evasion strategy (1997) (0)
TIRAP Occurring Loss-of-Function Variant of MyD88 Adaptor-Like D96N Is a Naturally (2010) (0)
T Cell Responses Induced by Adenoviral Vectored Vaccines Can Be Adjuvanted by Fusion of Antigen to the Oligomerization Domain of C 4 b-Binding Protein (2012) (0)
Development of a CTL inducing vaccine against plasmodium falciparum using a combination of delivery systems (1998) (0)
Lack of Association between Toll-Like Receptor 2 Polymorphisms and Susceptibility to Severe Disease Caused by <italic toggle='yes'>Staphylococcus aureus</italic> (2004) (0)
randomized , non-blinded trial of DNA and MVA therapeutic vaccines based on hepatitis B virus surface protein for chronic HBV infection (2017) (0)
Correction: Host Genetic Factors and Vaccine-Induced Immunity to HBV Infection: Haplotype Analysis (2011) (0)
Safety, immunogenicity, and efficacy results of a phase II trial of therapeutic vaccines for chronic HBV in the Gambia. (2004) (0)
Liver-stage vaccines for malaria (2013) (0)
Diagnosis of indigenous sprue / celiac disease with the help of gliadinepitopen (2000) (0)
Clinical Evaluation Of New Viral Vectored Vaccines Targeting The Plasmodium Falciparum Blood-Stage Antigens; Msp1 And Ama1 (2011) (0)
In vivo cross-reactivity of wheat and rye T-cell epitopes in celiac disease (2003) (0)
Malaria-Exposed Africans Tested by Three T Epitopes in Plasmodium falciparum Unique T Cell Effector Functions Elicited by Magdalena Plebanski (2001) (0)
Pool sequencing of naturally bound peptides from the HLA class II DQ2 allele and use of this data for T-cell epitope prediction in coeliac disease (1996) (0)
Possible immuno-modulatory activity of gliadin by interference with antigen processing (1997) (0)
therapeutic epitopes and their uses (2003) (0)
Correction: Multiple functions of human T cells generated by experimental malaria challenge (2011) (0)
Protection from liver-stage malaria is dependent on a fine balance between the number of infected hepatocytes and effector CD8+ T cells (2014) (0)
Host Resistance to Tuberculosis is Associated with Variation of the Vitamin D Receptor Gene but Not the Natural Resistance Associated Macrophage Protein Gene (1997) (0)
Gene Modulates Endotoxin Tolerance A Common Haplotype of the TNF Receptor 2 (2011) (0)
DNA-Modified Virus Ankara and Other Heterologous Prime-Boost Immunization Strategies for Effector T Cell Induction (2004) (0)
Host genetic variants near the PAX5 gene locus associate with susceptibility to invasive group A streptococcal disease (2019) (0)
Polymorphism and the HLA DPB1 locus: 8 new alleles (1994) (0)
GEOGRAPHIC-DISTRIBUTION OF ALPHA-GLOBIN AND BETA-GLOBIN GENE-CLUSTER POLYMORPHISMS (1989) (0)
Gene-Based Malaria Vaccines (2009) (0)
Erratum: Genetic variability and linkage disequilibrium within the HLA-DP region: Analysis of 15 different populations (Tissue Antigens (2001) 58 (431)) (2001) (0)
Functional variation in the IFNAR2 and IL10RB genes linked to persistent HBV infection. (2004) (0)
Methods and reagents for production of a CD8 + T cell immune response against Melanoma (1998) (0)
Dengue haemorrhagic fever: Double edged sword of HLA class I restricted responses? (1997) (0)
Epitope diagnostique et therapeutique, et plante transgenique (2000) (0)
Genetic Regulation of Acquired Immune Responses to Antigens of Mycobacterium tuberculosis: a Study of Twins in West Africa (2001) (0)
361 Cholesteryl ester transfer protein (CETP)ILE405VAL polymorphism affects the rate of fibrosis development in chronic hepatitis C virus infection (2003) (0)
Is Suppressed by Responses after Vaccination or Natural Exposure γ The Induction and Persistence of T Cell IFN (2011) (0)
Recombinant Adenovirus Overcome by Prior Immunization with a Efficacy of Protein Vaccines Can Be Enhance the Immunogenicity and Protective The Requirement for Potent Adjuvants To (2011) (0)
Erratum to Correction: Dengue Research Funded by the European Commission-Scientific Strategies of Three European Dengue Research Consortia (The PLOS Neglected Tropical Diseases Staff) (2014) (0)
Viral vectored blood-stage malaria vaccines induce B cell responses in humans that can be boosted by controlled malaria infection (2014) (0)
Methods and reagents for production of a CD8 + T cell immune response to hepatitis B or C (1998) (0)
Malaria vaccines: the stage we are at (2011) (0)
Binding characteristics of synthetic ligands from A-gliadin to the coeliac disease susceptibility molecules HLA-DQ2/8, and the linked molecules HLA-DR3/4 (1997) (0)
Genetic susceptibility to common mycobacterial diseases (2010) (0)
HLA-B27 TYPING BY PCR OF A GREENLAND POPULATION (1992) (0)
Development of an objective gene expression panel as an alternative to self-reported symptom scores in human influenza challenge trials (2017) (0)
Stefano Colloca Induce Potent Cellular Immunity Across Multiple Species Vaccine Vectors Derived from a Large Collection of Simian Adenoviruses (2011) (0)
Native American gene flow into Polynesia predating Easter Island settlement (2020) (0)
falciparum Plasmodium Exposure Is Suppressed by Responses after Vaccination or Natural γ The Induction and Persistence of T Cell IFN-and (2007) (0)
Non-HLA gene polymorphism in pulmonary tuberculosis (1998) (0)
Rational Zika vaccine design via the modulation of antigen membrane anchors in chimpanzee adenoviral vectors (2018) (0)
Abstracts of the Eighth EDCTP Forum, 6–9 November 2016 (2017) (0)
Immunopeptidomic Analysis of BoLA-I and BoLA-DR Presented Peptides from Theileria parva Infected Cells (2022) (0)
Adenovirus-prime and baculovirus-boost heterologous immunization achieves sterile protection against malaria sporozoite challenge in a murine model (2018) (0)
Protection from Plasmodium berghei infection by priming to a single CTL epitope with vaccine carriers that do not require adjuvants (1997) (0)
The HLA-DPB1 locus: Polymorphism and population genetics (1992) (0)
Development of a Molecular Adjuvant to Enhance Antigen-Specific CD8+ T Cell Responses (2018) (0)
OC 8552 EFFICACY OF THE CHAD63-MVC ME-TRAP VECTORED MALARIA VACCINE CANDIDATE IN 5–17 MONTHS OLD INFANTS AND CHILDREN IN BURKINA FASO (2019) (0)
A VLP for validation of the Plasmodium falciparum circumsporozoite protein junctional epitope for vaccine development (2021) (0)
Safety and efficacy of novel malaria vaccine regimens of RTS,S/AS01B alone, or with concomitant ChAd63-MVA-vectored vaccines expressing ME-TRAP (2018) (0)
A tool for evaluating heterogeneity in avidity of polyclonal antibodies (2023) (0)
Assessment of novel vaccination regimens using viral vectored liver stage malaria vaccines encoding ME-TRAP (2018) (0)
The Search for a Malaria Vaccine: Clinical Trials of DNA-MVA and other Prime-Boost Approaches (2003) (0)
Humoral immunogenicity of ChAd63_MVA ME-TRAP vaccination in African infants and children (2014) (0)
956 Molecular interactions of hepatitis B virus nucleocapsid and envelope peptides with HLA-DR1, -DR3, -DR7 and -DR13 glycoproteins (2003) (0)
Adjuvanting a viral vectored vaccine against pre-erythrocytic malaria (2017) (0)
Increased sample volume and use of quantitative reverse-transcription PCR can improve prediction of liver-to-blood inoculum size in controlled human malaria infection studies (2015) (0)
Methods and reagents for production of a CD8 + T cell immune response (1998) (0)
Invariant V (cid:2) 14 Chain NKT Cells Promote Plasmodium berghei Circumsporozoite Protein-Speciﬁc Gamma Interferon- and Tumor Necrosis Factor Alpha-Producing CD8 (cid:1) T Cells in the Liver after Poxvirus Vaccination of Mice (2005) (0)
Safety and immunogenicity of ChAdOx1 nCoV-19 (AZD1222) vaccine in adults in Kenya: a phase 1/2 single-blind, randomised controlled trial (2023) (0)
STING-pathway modulation to enhance the immunogenicity of adenoviral-vectored vaccines (2022) (0)
Safety and efficacy of ChAdOx1 RVF vaccine against Rift Valley fever in pregnant sheep and goats (2019) (0)
Publisher Correction: Adjuvanting a viral vectored vaccine against pre-erythrocytic malaria (2019) (0)
Epitope Selection Nonbinding Terminal Regions of Ligands in Cell Epitopes , and the Influence of the from HLA-DR and-DQ Molecules to Predict T Use of Complete Eluted Peptide Sequence Data (1998) (0)
Modification of Adenovirus vaccine vector-induced immune responses by expression of a signalling molecule (2020) (0)
HLA-B27 SUBTYPING BY SINGLE-STRAND CONFORMATION POLYMORPHISMS (SSCP) IN CAUCASOIDS, NEGROIDS AND INUITS FROM GREENLAND (1992) (0)
Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South Africa1 (2012) (0)
Immunogenicity of a pre-erythrocytic-stage malaria insert ME-trap encoded by novel simian adenoviral vectors (2005) (0)
Cöliakidiagnose using a gliadin epitope (2000) (0)
HLA-DPBI and malaria in West Africa (1994) (0)
Genome-wide association study of leprosy in Malawi and Mali (2022) (0)
Challenge in Mice Aerosol Mycobacterium tuberculosis against but Not Spleen , Correlate with Protection Cytokine-Producing Th 1 Cells in the Lung , Multifunctional , High-Level (2008) (0)
Elevated risk of invasive group A streptococcal disease and host genetic variation in the human leucocyte antigen locus (2019) (0)
How To Challenge – Current Design, Participant and Microbiological Considerations of Human Volunteer Challenge (2020) (0)
The Human Leukocyte Antigen Locus and Rheumatic Heart Disease Susceptibility in South Asians and Europeans (2020) (0)
Production of a high purity, C‐tagged hepatitis B surface antigen fusion protein VLP vaccine for malaria expressed in Pichia pastoris under cGMP conditions (2022) (0)
BIRC6 modiﬁes risk of invasive 1 bacterial infection in Kenyan 2 children. 3 (2022) (0)
Language continuity despite population replacement in Remote Oceania (2018) (0)
A frequent ancestral NFKB1 variant predicts risk of infection or allergy (2022) (0)
Comparative performances of machine learning methods for classifying Crohn Disease patients using genome-wide genotyping data (2019) (0)
ACTR1A has pleiotropic effects on risk of leprosy, inflammatory bowel disease and atopy (2022) (0)
Ancestry-specific analyses of genome-wide data confirm the settlement sequence of Polynesia (2022) (0)
Safety and immunogenicity of the candidate malaria vaccines FP9 ME-TRAP and MVA METRAP in semi-immune adult males [MIM-OK-87312] (2005) (0)
Correction: Recombination-Mediated Genetic Engineering of a Bacterial Artificial Chromosome Clone of Modified Vaccinia virus Ankara (MVA) (2011) (0)
Common genetic variants in the immunoglobulin heavy chain locus and their differential impact on group A streptococcal disease susceptibility: a comparative meta-analysis of genetic susceptibility studies (2017) (0)

This paper list is powered by the following services:

Other Resources About Adrian V. S. Hill

What Schools Are Affiliated With Adrian V. S. Hill?

Adrian V. S. Hill is affiliated with the following schools: